Exploring the Microglia Proteome in an Alzheimer's disease cellular model by Correani, Virginia
  
 
 
 
 
 
 
DOTTORATO DI RICERCA IN BIOCHIMICA 
CICLO XXVI (A.A. 2010-2013) 
 
 
 
EXPLORING THE MICROGLIA PROTEOME 
IN AN ALZHEIMER’S DISEASE CELLULAR MODEL 
 
 
DOTTORANDA 
VIRGINIA CORREANI 
 
 
TUTOR                                                                             
PROF.SSA M. EUGENIA SCHININÀ                                  
COORDINATORE 
PROF. FRANCESCO MALATESTA 
 
 
 
DICEMBRE 2013 
  
 
 
 
 
 
 
DOTTORATO DI RICERCA IN BIOCHIMICA 
CICLO XXVI (A.A. 2010-2013) 
 
 
 
EXPLORING THE MICROGLIA PROTEOME 
IN AN ALZHEIMER’S DISEASE CELLULAR MODEL 
 
 
DOTTORANDA 
VIRGINIA CORREANI 
 
 
TUTOR                                                                             
PROF.SSA M. EUGENIA SCHININÀ                                  
COORDINATORE 
PROF. FRANCESCO MALATESTA 
 
 
 
 
 
 
 
 
 
 
 
 
 
DICEMBRE 2013 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cover image from: 
R&D System 
(http://www.rndsystems.com/Cytokine_cb08i2_IL1betaNeuroinflammation.aspx) 
 I 
TABLE OF CONTENTS 
 
CHAPTER 1. INTRODUCTION ............................................................................ 1 
1.1 MICROGLIA  ....................................................................................................... 1 
1.1.A RESTING MICROGLIA .................................................................................. 2 
1.1.B ACTIVATED MICROGLIA FUNCTIONS .......................................................... 2 
1.2 MICROGLIA AND NEURODEGENERATION .......................................................... 5 
1.2.A MICROGLIA IN ALZHEIMER’S DISEASE .......................................................... 6 
1.2.B OXIDATIVE STRESS ....................................................................................... 8 
CHAPTER 2. AIM OF THE STUDY ................................................................... 11 
CHAPTER 3. EXPERIMENTAL SETUP ............................................................ 12 
3.1 CELL CULTURE CONDITIONS  ........................................................................... 12 
3.1.A STABLE ISOTOPE LABELING WITH AMINO ACIDS IN CELL CULTURE 
(SILAC) ........................................................................................................... 12 
3.1.B TRANSIENT TRANSFECTION OF BV2 CELL LINE ........................................... 13 
3.2 Aβ25-35 PREPARATION AND CELL TREATMENT ................................................. 13 
3.3 CHARACTERIZATION OF AMYLOID-INDUCED BV2 ACTIVATION AT 
CELLULAR LEVEL .................................................................................................. 13 
3.3.A EXOCYTIC ACTIVITY ................................................................................... 13 
3.3.B PRO-INFLAMMATORY CYTOKINES EXPRESSION ........................................... 14 
3.4 DETERMINATION OF INTRACELLULAR OXIDATIVE STRESS ............................ 14 
3.4.A GSH AND GSSG MEASUREMENTS .............................................................. 14 
3.4.B REACTIVE CARBONYLS MEASUREMENT ....................................................... 15 
3.5 PROTEOME SAMPLE PREPARATIONS ............................................................... 15 
3.5.A ENRICHMENT OF THE CYTOSOLIC AND ORGANELLE COMPARTMENTS .......... 15 
3.5.B CO-IMMUNOPRECIPITATION OF 14-3-3ε .................................................... 15 
3.5.C ENRICHMENT OF PLASMA MEMBRANE PROTEINS BY SEQUENTIAL TWO 
PHASE SYSTEMS .................................................................................................. 16 
3.5.D ENRICHMENT OF THE MICROGLIA REDOXOME ........................................ 18 
3.6 PROTEOMIC PROFILINGS ................................................................................. 19 
 II 
3.6.A BI-DIMENSIONAL ELECTROPHORESIS OF PROTEINS FROM THE 
CYTOSOLIC AND ORGANELLE COMPARTMENTS .................................................... 19 
3.6.B SDS-PAGE OF IMMUNOPRECIPITATED COMPLEXES AND PLASMA 
MEMBRANE ENRICHED FRACTIONS ...................................................................... 20 
3.6.C IN-GEL DIGESTION ..................................................................................... 20 
3.6.D MALDI-TOF ANALYSIS OF 2-DE SPOTS .................................................... 20 
3.6.E LC-MS/MS ANALYSES ................................................................................ 21 
3.6.F MASS SPECTRA ANALYSIS ............................................................................ 23 
3.7 VALIDATION OF PROTEOMIC IDENTIFICATION BY IMMUNODETECTION ......... 23 
CHAPTER 4. RESULTS ........................................................................................ 25 
4.1 CHARACTERIZATION OF AMYLOID-INDUCED BV2 ACTIVATION AT CELLULAR 
LEVEL ................................................................................................................... 25 
4.2 PROTEOMICS ANALYSIS OF THE CYTOSOLIC AND  
ORGANELLE COMPARTMENTS .............................................................................. 26 
4.3 DEFINING THE PROTEIN-PROTEIN INTERACTION NETWORK OF THE  
EPSILON 14-3-3- PATHWAY IN MICROGLIA TOXIC ACTIVATION ........................... 31 
4.4 QUANTITATIVE PROTEOMIC ANALYSIS OF PLASMA MEMBRANE PROTEINS 
DURING NEUROINFLAMMATION ........................................................................... 34 
4.5 OXIDATIVE STRESS INDUCED BY Aβ25–35 IN BV2 CELLS ................................. 35 
4.6 REDOX SHOTGUN PROTEOMICS FOR THE IDENTIFICATION OF  
REVERSIBLY OXIDIZED PROTEINS ......................................................................... 37 
CHAPTER 5. DISCUSSION & CONCLUSIONS ............................................... 40 
CHAPTER 6. REFERENCES ............................................................................... 49 
ACKNOWLEDGMENTS ...................................................................................... 62 
APPENDIX I ........................................................................................................... 63 
APPENDIX II .......................................................................................................... 72 
Chapter 1. Introduction 
 
1 
 
CHAPTER 1 
 
INTRODUCTION 
 
1.1 Microglia 
Microglial cells represent one of the three glial sub-population of the Central 
Nervous System (CNS).They have been described for the first time in 1899 by Franz 
Nissl, who named them “rod cell” because of the shape of the rod-shaped cell body. 
However, only many years later, Pio del Rio-Hortega, using the silver carbonate 
staining, identified these cells as a population independent from astrocytes and 
oligodendrocytes and coined the term “microglia”. Based on morphological 
similarity with macrophages, he hypothesized that microglial cells derive from 
circulating blood monocytes and that they have the ability to transform from resting 
cells to activated macrophages. Indeed, unlike the other cells of the nervous system, 
microglia originate from hematopoietic stem cells in the fetal yolk sac. During the 
early phases of the embryonic development, before the formation of the blood brain 
barrier, the myeloid progenitors of microglia migrate toward the developing brain 
where they differentiate into mature microglial cells (Ransohoff & Cardona, 2010). 
At the end of the fetal development, microglia have settled in all regions of the 
nervous system, including the retina. In the adult brain,microglia represent about 
12% of the nervous cells and are distributed differently among brain regions: 
predominantly in the gray matter, with the highest concentration in hippocampus, 
olfactory telencephalon, basal ganglia and substantia nigra (Lawson et al., 1990). 
In the mature brain, microglial cells are generally found in quiescent form, 
characterized by a branched shape. However, morphological studies, based on the 
silver carbonate staining, have shown the existence of other types of morphology: an 
amoeboid and some intermediate forms. This morphological classification is also 
used to describe the state of activation of the microglia: the quiescent highly 
ramified cells undergo reversible 
morphological transitions (Fig. 1.1) 
toward an active and phagocytic 
state, characterized by an amoeboid 
morphology, getting through to 
“primed” states with an intermediate 
shape between ramified and 
amoeboid (Kim & de Vellis, 2005). 
 Fig. 1.1 Transformation of resting microglia (left 
end) into activated (right end; Kreutzberg, 1996). 
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1.1.a Resting microglia 
In healthy brain, microglia are in a resting state characterized by a highly ramified 
morphology. However, these cells are not really inactive. In vivo studies on 
transgenic mice brain by two- photon microscopy have shown that the cellular 
processes of microglia are highly motile and in continuous remodeling. These 
membranous processes sample randomly the extracellular environment and remove 
metabolites and cellular debris accumulated in the parenchyma. This activity of 
perception and interpretation of environmental signals is essential for the 
establishment of a fast response to pathogens and brain lesions (Nimmerjahn et al., 
2005). 
Usually, the microglial activation is triggered by the recognition of exogenous 
factors not present in the nervous system under normal conditions (e.g. microbial 
structures and serum components), factors usually present in low concentration (e.g. 
intracellular constituents), and molecules present in an abnormal state (e.g. 
aggregated proteins; Hanisch & Kettenmann, 2007). 
In order to detect and interpret all these potential insults, microglia constitutively 
express different kind of receptors: the Toll like receptors (TLRs) family; scavenger 
receptors (e.g. CD36 and MARCO); integrin receptors (e.g. MAC1); IgG 
superfamily receptors (e.g .receptor for advanced glycation end products); other 
receptors for chemokines, cytokines, complement factors and immunoglobulins 
(Block et al., 2007). 
Interestingly, the brain evolved various safety measures to keep microglia in a 
resting state. These kind of regulatory mechanisms allow neurons to inhibit 
microglial activation until tissue homeostasis is perturbed. For example, various 
secreted neurotransmitters, such as dopamine and noradrenaline, show modulatory 
effects on microglia (Faber & Kettenmann, 2005). Furthermore, CD200, a 
membrane glycoprotein expressed by neurons, interacts with its cognate receptor on 
microglia (CD200R) to deliver regulatory signals (Hoek et al., 2000). Also some 
chemokines produced by neurons, as fractalkine (CX3CL1), can restrict microglial 
activity when bound their receptors (Cardona et al., 2006). The loss of these signals, 
due to the impairment of neurons, triggers microglial response and activation. 
1.1.b Activated microglia functions 
Beyond morphological changes, the activation process is characterized by an 
increased proliferation, migration toward the lesion and some dramatic changes in 
their function. In fact, microglia adjust the response according to environmental 
changes and to the nature of injury that affect the CNS (Ransohoff & Perry, 2009). 
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Depending on the environment in which microglia are activated, they can either take 
on a “classically activated” (also called ε1) phenotype or an “alternatively 
activated” (also called εβ) phenotype (εantovani et al., 2004). M2 microglia are 
typically considered less inflammatory than M1 cells and are characterized by 
reduced nitric oxide production and increased anti-inflammatory cytokine 
production (Lucin & Wiss-Coray, 2009). A brief description of the principal 
microglial functions is reported below. 
 
Phagocytosis 
An efficient phagocytic process is necessary for the maintenance of tissue 
homeostasis. Antigens (i.e. cellular debris, apoptotic cells, viruses, bacteria, 
abnormal proteins and peptides) may be recognized by receptors directly. Some of 
these receptors serve to tether the phagocyte and the target together; others trigger 
internalization, such as TLRs and scavenger receptors (Underhill & Goodridge, 
2012; Sierra et al., 2013). In addition, engulfment can also triggered by soluble 
opsonins that bind to receptors and send an internalization signal. Antibodies and 
proteins of the complement system bind to phagocyte Fc receptors and complement 
receptor, respectively, and mediate phagocytosis. Particles are thus incorporated into 
a coated vesicle, the phagosome, which in turn merges with lysosomes. Inside the 
lysosomal compartment, the swallowed material is subjected to phagocytic oxidase, 
which promotes the production of oxygen free radicals (ROS), and to inducible 
nitric oxide synthase (iNOS), and it is digested by means of numerous lysosomal 
proteases. 
Oxidative Burst 
Microglia can release a variety of cytotoxic substances. Indeed, microglial cells are a 
potent source of free radicals. The protein complex involved in the production of 
extracellular ROS is NADPH oxidase, an enzymatic complex composed of different 
cytoplasmic and membrane subunits, which catalyzes the conversion of oxygen to 
superoxide when activated in response to different environmental stimuli (Babior, 
1999). Following microglia activation, the regulatory subunits dispersed into the 
cytosol translocate on the membrane to form the active enzymatic complex through 
the binding of catalytic subunits (Wilkinson & Landreth, 2006). 
Furthermore, NADPH oxidase seems to be crucial for microglial cell signaling. 
Indeed, the increase of superoxide and intracellular ROS are thought to be involved 
in the modification of gene expression by means of kinase cascades and the 
activation of transcription factors. These events culminate in the acquisition of an 
activated morphology, proliferation and production of pro-inflammatory molecules, 
such as nitric oxide (NO) by expression of iNOS (Qin et al., 2004). Both ROS and 
NOS (Nitric Oxide Species), can directly damage cells and lead to neuronal cell 
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death. The cytotoxic secretion is addressed to destroy infected neurons, viruses and 
bacteria, but can also cause many collateral damage to healthy neurons. 
Innate immune response 
Other molecules are secreted by activated microglia, such asinterleukin-1 (IL-1) and 
tumor necrosis factor α (TNF-α), are necessary for the establishment of the 
inflammatory process. These two cytokines act both in an autocrine way, through 
the activation and recruitment of local glia (microglia and astrocytes), and in a 
paracrine way, attracting leukocytes, monocytes and other cells of the immune 
system. Nevertheless, it has been demonstrated that elevated levels of these two 
cytokines can cause neuronal death supporting the hypothesis that a chronic 
inflammatory response can lead to neural damage on a large scale, as microglial 
cells impair the brain in an attempt to eliminate the infection (Harry & Kraft, 2008). 
Microglial cells, like macrophages, also secrete other pro-inflammatory cytokines, 
such as IL-6 and IL-8, which attract T lymphocytes and promote the growth and 
differentiation of B lymphocytes, and immunomodulatory cytokines, such as IL-12 
(Town et al., 2005). 
Adaptive immune response and antigen presentation 
Activated microglia can also work as antigen presenting cells (APC) similarly to 
peripheral macrophages, dendritic cells and lymphocytes B. 
In fact, after the recognition, microglia can swallow and process the antigen in order 
to rapidly present it to T lymphocytes through the major histocompatibility complex 
(εHC) types I and II (O’Keefe et al., 2002; Beauvillain et al., 2008). The MHC-I, 
potentially expressed by all nucleated cells, is able to present antigen to CD8+ 
cytotoxic T lymphocytes; the MHC-II, expressed by professional APC cells and 
macrophages, is recognized by CD4+ helper T lymphocytes. Then T lymphocytes, 
after passing the blood-brain barrier, are physically in contact with the antigen and 
co-stimulatory molecules (i.e. CD40 and B7) on the surface of reactive microglia. 
This process results in a full activation, differentiation and proliferation of 
lymphocyte cells specific for a certain antigen. The activated lymphocytes fulfill 
different tasks: the CD4+ cells (helper) recruit macrophages and eosinophils; the 
CD8+ cells secrete proteins able to create pores in the plasma membrane of target 
cells and induce apoptosis. 
Suppression of inflammation and tissue repair 
In the appropriate microenvironment, microglia can also produce anti-inflammatory 
cytokines, such as IL-10, IL-4 and TGF-ȕ, in order to prevent a too long lasting 
inflammatory response. Furthermore, they can inhibit phagocytosis, proliferation, 
cell migration and chemotaxis of macrophages (Strle et al., 2002; Boche et al., 
2006; Harry & Kraft, 2008). 
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At the same time, microglia undertakes a series of actions to facilitate the regrowth 
of nerve tissue through the secretion of neurotrophic growth factors (e.g. brain-
derived neurotrophic factor and glial cell-derived neurotrophic factor), stripping of 
synapses and removal of extracellular glutamate (Trapp et al., 2007; Hanish & 
Kettenmann, 2007). 
 
1.2 Microglia and neurodegeneration 
Since neurons have limited proliferative and regenerative capacities, the nervous 
system is extremely vulnerable to sustained inflammatory processes (Fanfara et al., 
2008; Gao & Hong, 2008; Khoury & Luster, 2008). A large number of data 
indicates that an excessive and uncontrolled inflammatory processes may contribute 
to the loss of neurons during neurodegenerative diseases, but how and how much 
inflammation is involved in the chronic progression of these diseases remains 
largely unknown (Perry et al., 2010). 
The role of inflammation has been demonstrated in part by stimulation of the cells 
with environmental stimuli (e.g. aggregated proteins): in these cases, it is often 
observed that a robust secretion of cytotoxic and/or inflammatory factors can 
accelerate neuronal death (Liu & Hong, 2003). Moreover, the persistent microglial 
activation was studied using different neurotoxins, such as MPP+ (1-methyl-4-
phenylpyridine) and MnEBDC (manganese ethylene bisdithiocarbamate): neuronal 
sensitivity increases proportionally with the quantity of microglia added to neuron 
cell cultures (Zhou et al., 2005). Furthermore, treatment with anti-inflammatory 
drugs (e.g. aminopiridazine and glucocorticoids), which suppress the activation of 
microglial cells, inhibits neurodegeneration (Craft et al., 2004; Sugama et al., 2009). 
The extent of immune system reaction depends on the level of injury, its duration, 
the genetic predisposition of an individual and contemporary events (e.g. other 
diseases or stress); the combined effects of these events could determine the role, if 
neuroprotective or neurotoxic, should have the microglia. If an inflammatory 
reaction is temporally regulated and the antigen is removed, the inflammation has a 
beneficial effect. However, if the insult exceeds the threshold then a chronic 
inflammatory process is established (Gao & Hong, 2008). Therefore, the microglial 
activity during neurodegenerative diseases could represent a “double-edged sword”: 
in the early phase, their role is essential for the removal of neurotoxic peptides; 
however, with the progression of the disease, it is observed a progressive 
dysfunction of the microglia, which reduces its phagocytic ability and increases its 
pro-inflammatory and neurotoxic functions, up-regulating the production of 
cytokines and ROS (Hickman et al., 2008; Aguzzi et al., 2013). 
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1.2.a Microglia in Alzheimer’s disease 
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder characterized 
by a progressive loss of neurons and synapses mostly in the cerebral cortex (Uylings 
& de Brabander, 2002). These events are associated with the presence of 
extracellular plaques and of intracellular neurofibrillary tangles. 
The latter are made up of the microtubule-associated protein Tau that, following 
hyperphosphorylation, dissociates from microtubules and aggregates in the 
cytoplasm. This event lead to microtubule network destabilization and cell 
dysfunction (Fig. 1.2; Chun et al., 2007). 
Fig. 1.2 Representation of microtubules disintegration induced by Tau hyperphosphorylation and 
aggregation during Alzheimer’s disease (from “Alzheimer's Disease Education and Referral Center, a 
service of the National Institute on Aging”). 
The extracellular senile plaques consist of insoluble proteinaceous deposits of 
aggregated amyloid ȕ peptides (Aȕ) in particular the 42- (Aȕ1-42) and 40-residues 
(Aȕ1-40) species (Maler et al., 2007). These peptides are generated by the sequential 
action of two proteases, the ȕ-secretase and the Ȗ-secretase (Esch et al., 1990), 
which cleave the “Amyloid Precursor Protein” (APP), an integral plasma membrane 
protein (Fig. 1.3; Goedert & Spillantini, 2006). Mutations of the APP gene are 
associated to a familiar form of Alzheimer’s disease characterized by an autosomal 
dominant inheritance and early onset, usually before age 65 (Blennow et al., 2006). 
All the known mutations are located in the cleavage sites of secretases and increase 
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amyloid production (Selkoe, 1997), particularly of Aȕ1-42, the amyloid species more 
prone to aggregation. However, the majority of AD cases are sporadic rather than 
familial. The best known genetic risk factor is represented by the inheritance of the 
İζ allele of the apolipoprotein E (APOE) gene (εahley et al., 2006); this allele 
increase the probability to develop AD by three times in heterozygotes and 15 times 
in homozygotes. 
Fig. 1.3 Representation of ȕ amyloid plaque formation (from “Alzheimer's Disease Education and 
Referral Center, a service of the National Institute on Aging”). 
The amyloid fibrils and plaque, have long been thought to be responsible of 
neurodegeneration observed in AD (Hardy & Higgins, 1992; Lansbury & Lashuel, 
2006). Recently, clear evidences point to the role of soluble amyloid oligomers as 
the major cause of neurotoxicity (Hardy & Selkoe, 2002; Haass & Selkoe, 2007). 
However, it is not fully understood how these sopramolecular species prime 
intracellular toxic effects but several evidence suggest that they interact with 
receptors or specific proteins on the plasma membrane of neuronal cells changing 
the intracellular environment (Larson & Lesné, 2012). 
Immunohistochemical studies demonstrated that microglia in a healthy brain are 
uniformly distributed between gray matter and white matter, while they are grouped 
around the amyloid deposits in an AD diseased brain (McGeer et al., 1987; Heneka 
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& O'Banion, 2007). Furthermore, in transgenic mouse models of AD, microglia are 
observed to accumulate within the core of amyloid plaques (Fig. 1.4; Frautschy et 
al., 1998), where they are able to phagocyte amyloid ȕ deposits (D’Andrea et al., 
2004). 
Fig. 1.4 Microglia seem to be clustered around amyloid deposits in brain of transgenic mice. Microglia 
(brown) were stained with anti-CD11b antibody, while senile-like plaques (green) were stained with 
Thioflavin-S (Khoury & Luster, 2008). 
Several data have shown that amyloid ȕ peptides may act on microglia as 
inflammatory stimuli to elicit a cellular-mediated response, leading to the release of 
immunomodulators (Akiyama et al., 2000; Eikelenboom et al., 2008). The majority 
of these factors is believed to induce or exacerbate neurodegeneration by causing 
neuronal apoptosis through mechanisms not yet fully understood (Serrano-Pozo et 
al., 2011). 
 
1.2.b Oxidative stress 
Oxidative stress is a pathological condition arising when the production of oxidizing 
species (i.e. ROS and NOS) overcomes the capacity of the antioxidant defences to 
remove the reactive intermediates or damaged molecules. This redox unbalance 
could play a critical role in the onset and progression of neurodegenerative 
pathologies, including AD (Praticò, 2008; von Bernhardi & Eugenín, 2012). Indeed, 
brain is particularly vulnerable to oxidative stress due to its high aerobic metabolic 
rate, the paucity of antioxidant defences, the high lipid content, especially 
polyunsaturated fatty acids, and the post-mitotic nature of neurons. The oxidative 
stress could be further intensified by concurrent events as mithocondrial 
dysfunctions, presence of aggregated proteins and activated microglial cells. 
The alteration of the normal redox state broadly affects cells and is responsible of 
covalent modifications of proteins, lipids and nucleic acids (Markesbery et al., 
1997). Various evidences of damage induced by free radicals have been reported 
within specific brain region undergoing neurodegeneration. Concerning the AD 
pathology, markers of lipid peroxidation have been found in the cortex and in the 
hippocampus (Butterfield et al., 2002; Praticò & Sung, 2004); furthermore, markers 
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of protein oxidation, i.e. nitration and carbonylation, resulted increased in the brain 
of patients affected by AD (Hensley et al., 1998; Castegna et al., 2003; Boyd-
Kimball et al., 2005). 
However, proteins seems to be the major target of oxidative modifications because 
of their abundance in biological systems, and their high rate constants of reaction 
with the free radicals (Davies, 2005). 
One of the most relevant redox protein modification is represented by reversible S-
thiolation of cysteinyl residues. Even though cysteines are under-represented inside 
polypeptides, they play a pivotal role in the maintenance of thiol–disulfide 
homeostasis, protein structure and function. Indeed, cysteinyl residues on the protein 
surface are the most sensitive to an altered redox potential. The two main factors 
determining the susceptibility of cysteine residues in redox reactions are: i) the 
accessibility of the thiol within the protein three-dimensional structure; ii) the 
reactivity of the cysteine, which is in turn influenced by their enviroment. At a 
physiological pH, cysteine residues of cytoplasmic proteins have usually a pKa 
value near to 8.5 and remain in the protonated state in the normal reducing cellular 
environment. However, in redox-sensitive proteins, there are “active cysteines” 
showing a lower pKa due to the charge interaction with neighbouring positively 
charged amino acids; these thiols are more susceptible to oxidative changes (Rhee et 
al., 2000). 
Cysteine residues may undergo various modifications on their side chains (Fig. 1.5). 
Some of these, i.e. S-sulfinylation and S-sulfonylation, change irreversibly the 
chemical-physical properties of the cysteine. Conversely, other modification, such as 
S-sulfenylation, S-nitrosylation, formation of disulfide bridges or mixed disulfides 
with glutathione (S-glutathionylation) the major non-enzymatic antioxidant system, 
are reversible. In particular, this latter modification likely represents the main redox 
product due to the great abundance of cellular GSH, and to the quick conversion of 
cysteine-sulfenic acid and S-nitrosocysteine in S-glutathionylcysteine (Mieyal & 
Gallogly, 2008). 
Among these reversible modifications, S-glutathionylation and S-nitrosylation are 
particularly interesting due to some similarities with phosphorylation, such as 
enzymatic catalysis and specificity. Indeed, inside the cell, there are enzymes, like 
thioredoxin or glutaredoxin, able to catalyze the addition/removal of glutathione 
from target proteins (Lillig & Berndt, 2012; Ghezzi et al., 2013). Similar evidences 
are seen for S-nitrosylation where the level of nitrosocysteines seems to be indirectly 
regulated by nitrosoglutathione reductase (Janssen-Heininger et al., 2008). 
Furthermore, the oxidative modification of a cysteine is possible only if the 
chemical environment in which the residue is located determines, as described 
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above, a decrease in the cysteine pKa that favour deprotonation of its thiol group; 
this requirement, together with the accessibility of the residue, assures a degree of 
specificity. 
Fig. 1.5 Cysteines in their reduced form could undergo different reversible and irreversible redox 
modifications by the reaction with ROS, NO radicals or glutathione. ROS can cause vicinal thiols or 
thiols from different proteins to undergo intra- or intermolecular disulfide bridge formation, 
respectively. Glutathione, both in reduced and oxidized form, can cause S-glutathionylation of protein 
through two different mechanisms: formation of a mixed disulfide between GSH and protein thiols or 
disulfide exchange between GSSG and protein thiols. NO cause the S-nitrosylation of thiols. ROS 
cause the S-hydroxylation of thiols to form sulfenic acid. Sulfenic acid can further oxidize to sulfinic or 
sulfonic acids, which represent irreversible oxidations of thiols.  
Therefore, S-glutathionylation and S-nitrosylation may, during oxidative stress, not 
only protect proteins from irreversible modification resulting in their degradation, 
but may also represent a key mechanism for protein functional regulation and cell 
signalling both in physiological and pathological conditions (Dalle-Donne et al., 
2009).
REDOX MODIFICATION OF CYSTEINE
REVERSIBLE
Disulfide bridge
S-glutathionylation
S-nitrosylation
S-sulfenylation
IRREVERSIBLE
Intramolecular
Intermolecular
Sulfinic acid Sulfonic acid
GSH or GSSG
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CHAPTER 2 
 
AIM OF THE STUDY 
 
The aim of the present work, which are part of a wide long-term project, is the 
elucidation of the molecular basis that lead microglia to assume a chronic 
neuroinflammatory phenotype during neurodegenerative processes. In particular, we 
focused on the characterization of microglial response during a chronic stimulation 
with amyloid peptides through the analysis of changes in protein expression levels 
and the analysis of dynamic post-translational modification (PTM) of proteins. 
Thanks to its holistic point of view, proteomics is becoming a suitable approach to 
expand our understanding of basic biological processes and metabolisms, and their 
perturbation during pathological conditions. Therefore, proteomics has been 
extensively used for the study of the complexity of central nervous system and its 
cell populations in health and disease, with particular regard to neuronal 
development, activity and injuries (Bajès & Grant, 2009). Despite the growing 
relevance of microglia due to their involvement in neurodegeneration, only a limited 
number of genomic and proteomic studies were conducted  on microglial activation 
(Zhou et al., 2005; Glanzer et al., 2007). When these studies have been carried out 
using primary microglia cultured from pathological nervous tissues, molecular 
profiles were able to describe the microglial phenotype at the end point of the 
pathological activation, but failed to define the genomic or proteomic changes 
involved in the first steps of the complex pathway leading to the stable activation. 
With the aim to highlight molecular pathways involved in the establishment of a 
stable pro-inflammatory phenotype in microglia during Alzheimer’s disease, we 
used as experimental model an immortalized microglial cell line, named BV2, 
challenged with the synthetic amyloid ȕ βη-γη peptide (Aȕ25-35). To achieve a 
picture of the neuroinflammatory process as global as possible, we collected 
molecular details on different sub-proteomes (i.e. soluble and plasma membrane 
proteins, and cysteine redox reversible PTMs) applying both classical proteomics 
approach and new generation quantitative strategies. 
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CHAPTER 3 
 
EXPERIMENTAL SETUP 
 
3.1 Cell culture conditions 
The murine microglial cell line BV2, generated by infecting primary mouse 
microglial cultures with a v-raf/v-myc oncogene carrying retrovirus (Blasi et al., 
1990), were grown in DMEM (Invitrogen) supplemented with penicillin, 
streptomycin and 10% fetal calf serum (FCS; Sigma Aldrich); cultures were 
maintained at 37 °C in 5% CO2/95% humidified air atmosphere.  
Cell survival was quantified by cell counting using trypan blue exclusion. 
3.1.a Stable isotope labeling with amino acids in cell culture (SILAC) 
Stable isotope labeling of cultured cells represents a simple and accurate mass 
spectrometry-based approach for detecting differences in protein abundance among 
samples. Proteins and peptides of different proteomes can be differentially labeled 
through the metabolic incorporation of amino acid made of a distinct number of 
stable isotopic nuclei (e.g. 13C, 15N, 2H), introducing a predictable mass difference 
between peptides from two, or more, experimental conditions (Ong et al., 2002; Fig. 
3.1). 
Fig. 3.1 Principle of standard SILAC approach. A 
stably labelled amino acid in a cell-culture medium 
(e.g. ‘heavy’ arginine) is fully incorporated into the 
proteome of one cell population. Relative 
quantification experiments can easily be carried out 
using cells that were grown in normal media as the 
control state. Cell lysates from two conditions can 
be combined and purified through any number of 
steps. The proteins are then digested. As the two 
isotopic forms possess the same chemical-physical 
properties, the two forms of the peptides co-elute 
during chromatographic analysis; hence, a peptide 
ratio can be obtained for each mass spectrum, which 
allows the protein levels in the two populations to 
be relatively quantified (Steen & Mann, 2004). 
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When the SILAC approach was employed for comparative analysis, two different 
cultured BV2 cells were grown in media (SILAC media) based on arginine, lysine 
and leucine-free DMEM (Sigma Aldrich) supplemented with 10% dialyzed fetal 
bovine serum (FBS), 0.8 mM lysine, 0.8 mM leucine, penicillin and streptomycin. 
However, the two media were distinctive in formulations: one cell population was 
grown in presence of 12C14N-arginine (0.β8 mε; named “light arginine”), and the 
other population was grown in presence of 13C615N4-arginine (0.28 mM; named 
“heavy arginine”). We monitored the incorporation percentage in the proteome of 
the heavy amino acid by MALDI-TOF mass spectrometry of tryptic digests of 
selected SDS-PAGE bands (see paragraphs 3.6 b-d). 
3.1.b Transient transfection of BV2 cell line 
BV2 cells grown in SILAC media were transiently transfected with the expression 
vector pcDNA3.1/V5-His containing the cDNA of the epsilon isoform of 14-3-3 
(kindly supplied by Standaert’s group). The protein expressed by this vector was 
tagged at the C-terminal end with the two epitopes V5 (GKPIPNPLLGLDST) and 
His6. The transfection was performed using Lipofectamine® 2000 reagent 
(Invitrogen) according to the manufacturer. 
 
3.2 Aβ25-35 preparation and cell treatment 
Synthetic Aȕ25-35 (GSNKGAIIGLM) and reverse Aȕ35-25 (MLGIIAGKNSG) peptides 
(Bachem) were dissolved in sterile, distilled water at a concentration of 1 mM and 
incubated for 72 h at 37°C to allow aggregation. 
BV2 cells were treated for 24 h with 50 μM amyloid peptides.  
Regarding the SILAC experiments, only cells grown in presence of 13C615N4-
arginine were treated with Aȕ25-35.  
 
3.3 Characterization of amyloid-induced BV2 activation at cellular level 
3.3.a Exocytic activity 
Exocytic activity was measured accordingly to the reduction rate of the dye 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) essentially as 
described (Hansen et al., 1989). This yellow, soluble in water, tetrazolium salt is 
converted into formazan, insoluble compound of color purple, by the mitochondrial 
enzyme succinate dehydrogenase, active only in viable cells. Moreover, in amyloid 
stressed microglia cells, the formed formazan is specifically extruded by exocytosis. 
Following 24 h treatment with Aȕ25-35 or Aȕ35-25, 10 ml of MTT solution (5 mg/ml) 
was added to each well and the incubation was continued for 3 h. Lysis buffer was 
prepared by dissolving 40% (w/v) sodium dodecyl sulphate (SDS) in deionised 
water; an equal volume of N,N-dimethylformamide was then added, and the pH was 
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adjusted to 4.7. After 3 h incubation with MTT, 100 ml of the lysis buffer was added 
to each well and the absorbance read at 570 nm on a Microplate Reader. These 
analysis were kindly performed by Prof. Cinzia Fabrizi (Department of SAIMLAL, 
Sapienza University of Rome). 
3.3.b Pro-inflammatory cytokines expression  
Total RNA was purified by 2x106 BV2 cells by a single extraction with Trizol 
(Invitrogen) and reverse transcribed by oligo(dT)15-18 primers and MML-V reverse 
trascriptase (Invitrogen). The cDNAwas amplified by Taq DNA polymerase in a 
thermal cycle (PerkinElmer Life Sciences) in the presence of primers for tumor 
necrosis factor alpha (TNF-α) (η’-primer, GAGCACTGAAAGCATGATCCG; γ’-
primer GCAGGTCTACTTTGGGATCATT). Conditions for TNF-α amplifications 
were as follows: 30 s at 94°C, 30 s at 64°C, 30 s at 72°C. Ten microliters of each 
PCR product were electrophoresed on 1% agarose gel and then visualized by 
ethidium bromide staining. The mRNA for GAPDH was used as reference. 
Quantitative analysis of the interleukin 1 ȕ (Iδ-1ȕ) was performed using the EδISA 
kit (R&D System). These analysis were kindly performed by Prof. Cinzia Fabrizi 
(Department of SAIMLAL, Sapienza University of Rome). 
 
3.4 Determination of intracellular oxidative stress 
3.4.a GSH and GSSG measurements 
Thirty microliter of 5% tricloracetic acid (TCA) were added to an aliquot of each 
cell pellets (~ 1x106 cells); all samples were incubated in ice at 4° C for 2 hr. After 
centrifugation, these samples were diluted 1:5 with 50 mM phosphate buffer pH 3.0 
and filtered through Micron YM-10 centrifugal filter device (Amicon). One 
microliter of each samples was used for the determination of the levels of GSH and 
GSSG by a HPLC equipped with electrochemical detector (ECD). The 
chromatographic analysis was performed using a Waters 626 pump system 
associated with a Waters 600S controller. The separations were performed by means 
of a chromatographic column Waters Atlantis (C18, 5 um particle diameter, 100A 
pore diameter, 4.6 x 250 mm column length) using as mobile phase 100% 50 mM 
phosphate buffer, pH 3, at a constant flow of 1 ml for minute. The analytes were 
quantified using a detection system CoulArray electrochemical detector (ESA 5600) 
equipped with four analytical cells containing electrodes; each cell can record the 
variation of current over time at a certain constant potential. The potential of each 
electrode can be controlled independently from -1000 mV to 2000 mV. For the 
determination of GSH and GSSG were used two cells placed respectively at the 
potential of 700 mV and 850 mV. Calibration curves for GSH and GSSG were 
obtained by injecting 10 μl of standard solutions in the concentration range 1 mM - 
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100 mM. These analysis were kindly performed by Dr. Alberto Macone 
(Department of Biochemical Sciences, Sapienza University of Rome). 
3.4.b Reactive carbonyls measurement 
Protein carbonyl measurement was performed after stimulation of microglial cells 
for 72 h using the method of Cao & Cutler (1995). Briefly, each cell extract was 
divided into two parts, a test and a blank, with a volume of 1 ml. Four milliliters of 
12.5 mM 2,4-dinitrophenylhydrazine (DNPH) in 2.5 M HCl were added to the test 
while to the blank were added 4 ml of HCl 2.5 M. The two samples were then 
incubated at room temperature for 1 h, shaking every 10 minutes, precipitated with 
10% TCA (final concentration) and subsequently treated with a “strong” or “weak” 
washing procedures. The “strong” procedure was based on included a strong 
breaking of the precipitate with a homogenizer before further extraction with 4 ml of 
ethanol:ethyl acetate (1:1, v/v) for three times. The “weak” washing procedure was 
based on a weak breaking of the precipitate with a glass rod and an additional wash 
with 10% TCA prior to extraction with ethanol:ethyl acetate. The final pellets were 
dissolved in 1 ml of 6 M guanidine-HCl with 20 mM phosphate buffer: 
trifluoroacetic acid (TFA), pH 2.3, and left for 20 minutes at 37° C under stirring. 
Any insoluble material was removed by centrifugation. The content of reactive 
carbonyls (C) was calculated from their peak absorption at 370 nm using a molar 
absorption coefficient (İ) of ββ ε-1 cm-1. The final content of protein reactive 
carbonyls was expressed in nmol carbonyls/mg protein. This analysis was kindly 
performed by Dr. Alberto Macone (Department of Biochemical Sciences, Sapienza 
University of Rome). 
 
3.5 Proteome sample preparations 
3.5.a Enrichment of the cytosolic and organelle compartments 
For the 2-DE-based differential proteomics, lysates from Aȕ25-35 and Aȕ35-25 treated 
BV2 cells, and from untreated control samples underwent a subcellular fractionation 
by Qproteome Cell Compartment Kit (Qiagen). According to the protocol used, 
fractions enriched with cytosolic or with membrane proteins and proteins from the 
lumen of organelles except the nuclear components (named hereafter 
membrane/organelle proteins), respectively, were obtained from each lysate. 
3.5.b Co-immunoprecipitation of 14-3-3ε 
To enable elution of 14-3-3 interactors without antibody contamination, it is 
recommended to cross link the antibody to the insoluble support. Magnetic beads (~ 
32 μl slurry) with recombinant Protein G covalently coupled to the surface 
(Dynabeads protein G; Invitrogen) were incubated at 4°C overnight with ~ 4 μg of 
anti-V5 antibody (Invitrogen) on a rotator. After two washes with 0.2 M sodium 
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borate pH 9, the non covalent complexes beads/antibodies were incubated in 0.2 M 
sodium borate containing 20 mM dimethyl pimelimidate (DMP) for 1 h at room 
temperature on a rotator. After two times washes and a further 2 h incubation at 
room temperature on a rotator in a quenching buffer (0.2 M ethanolamine pH 9), 
covalently cross-linked complexes anti V5-beads were then resolved from 
uncovalent ones by sequential washes with 0.1 M glycine pH 2.8 (one time) and 
with PBS (three times). 
BV2 samples (~ 1x107 cells), from Aȕ25–35 treated (heavy labeled) cells or not (light 
labeled), were carefully washed 3 times with pre-chilled PBS buffer (1.37 M NaCl, 
27 mM KCl, 100 mM Na2HPO4, 18 mM KH2PO4) by centrifugation at 14000 rpm 
for 20 min at 4°C; the pellet was then dissolved in a RIPA-slightly modified lysis 
buffer, containing 50 mM Tris-HCl pH 7.4, 1 mM EGTA, 150 mM NaCl, 1% NP-
40, protease (Roche) and phosphatase (5 mM sodium fluoride, 1 mM sodium 
orthovanadate, 2.5 mM sodium pyrophosphate) inhibitors. Protein concentration was 
measured with Bradford reagent, on isolated aliquots. An equal amount of proteins 
(~ 1 mg) from both samples was then mixed and aspecific interactors pre-cleared by 
treatment with the magnetic beads for 1 h at 4°C on a rotator. The pre-cleared 
lysates were finally added and incubated with cross-linked antiV5-beads overnight 
at 4°C on a rotator. Afterward, the beads were washed with the lysis buffer (five 
times) and with PBS (one time). Then the proteins were eluted by treatment with 0.1 
M glycine pH 2.8 for 10 minutes and centrifugation at 1ζ000 rpm at ζ°C (γx 10 μl). 
3.5.c Enrichment of plasma membrane proteins by sequential two phase systems 
The plasma membrane enrichment were performed by two phase partition as 
previously reported (Schindler et al., 2008). Briefly, two-phase systems were 
prepared one day prior to usage from stock solutions of 200 mM Tris, adjusted to pH 
7.8 with sulfuric acid (Tris/SO42-), 40% (w/w) polyethylene glycol (PEG) 3350, and 
20% (w/w) dextran T500. The first phase (A) was prepared by mixing 1.035 g of 
dextran, 0.518 g of PEG, 0.75 g of Tris/SO42-, and 0.598 g of water and was 
incubated overnight at 4°C. Additional six phases (B-G) were prepared by mixing 
1.035 g of dextran, 0.518 g of PEG, 0.75 g of Tris/SO42-, and 0.698 g of water; also 
these phases was incubated overnight at 4°C. Prior to the experiment, top phases 
were removed from bottom phases and stored separately at 4°C. 
BV2 cells (~ 7x108), Aȕ25-35-treated (heavy labeled) and untreated (light labeled), 
were washed three times with PBS; cell pellets were then resuspended in 50 mM 
Tris containing protease inhibitors (Roche) and sonicated. The two samples were 
centrifuged at 1000 rpm for 10 min to remove unbroken cells and nuclei. The 
resulting supernatants were centrifuged at 14000 rpm for 30 min: the supernatants, 
containing cytosolic proteins, were quantified using Bradford assay; the pellets, 
containing plasma membrane-microsome compartment, were resuspended in the top 
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phase (PEG) A and combined in 1:1 proportion. As shown in figure 3.2, the top 
phase A was added to the bottom phase (dextran) A; the two resulting two-phase 
systems were mixed by inverting 20 times, vortexing, and inverting another 20 
times. The top phase A was transferred on the bottom phase B and new fresh top 
phase was added on the bottom phase A. In each of the following steps, all top 
phases were transferred onto the next bottom phase, and bottom phase A was again 
re-extracted with a fresh top phase. After each transfer, phases were mixed. The 
procedure was finished when the seven two phase systems were separated by 
centrifugation, resulting in a total of 7 top and 7 bottom phases. F and G top phases, 
both expected as enriched in plasma membrane, were mixed in order to increase the 
protein yield. Then these combined top phases were sedimented by 
ultracentrifugation for 1 h at 150000 g. The pellet was resuspended in sample buffer 
(1 mM Tris-HCl pH θ.8, ζ% SDS, 0.1% bromophenol blue, 10% ȕ-mercaptoethanol, 
10% glycerol) and proteins were resolved by mono-dimensional gel electrophoresis 
(see paragraph 3.6.b). 
 
Fig. 3.2 Schematic of the protocol to enrich brain plasma membranes. In the first step, the top 
phase “A”, containing microsomal fraction, were added to the bottom phase “A”. After phase 
separation, the top phase is transferred onto the fresh bottom phase “B”, and the bottom phase of the 
primary two-phase system, “A”, is covered with a fresh top phase. In the subsequent steps, the top 
phases are transferred one bottom phase along, always transferring the latest top phase onto a fresh 
bottom phase and re-extracting bottom phase “A” with a fresh top phase (for example, in the 3rd step, 
top phase “B” is transferred onto the fresh bottom phase “C”, top phase “A” is then transferred onto 
bottom phase “B”, and bottom phase “A” is finally covered with a fresh top phase). By doing so, 7 two-
phase systems (“A”–“G”) are obtained after the final 8th step, each containing a top and a bottom phase 
(adapted from Schindler et al., 2008). 
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3.5.d Enrichment of the microglia redoxome  
BVβ cells, treated with Aȕ25–35 or not, were washed and centrifuged three times with 
PBS; the pellet was finally dissolved in a lysis buffer containing 8M urea, 100mM 
NEM, 50 mM Tris-HCl pH 8.0, 2mM EDTA, 0.1% Triton X-100, protease and 
phosphatase (5mM sodium fluoride, 1mM sodium orthovanadate, 2.5mM sodium 
pyrophosphate) inhibitors. Cell extracts were incubated under rotation at 4°C for 15 
min and treated for three cycles of sonication/relaxation of 30 sec. Samples were 
centrifuged at 14000 rpm for 20 min at 4°C. Protein concentration was measured 
with Bradford reagent on isolated aliquots. 
Proteins involved in reversible oxidative modification of cysteines are detected as 
previously reported (McDonagh et al., 2009), with slight modifications. In brief, 
proteins (η00 μg) were precipitated from the cell extracts overnight at -20°C with 
nine volume of cold ethanol and pellet by centrifugation at 14000 rpm at 4°C for 15 
min. Protein pellets were dissolved in 180 μl of denaturing buffer containing 8ε 
urea, 4% CHAPS, 50 mM Tris-HCl pH 8.0 and 2mM EDTA. The reducing agent 
dithiotreitol (DTT) was then added to the final concentration of 20 mM, and samples 
were incubated for 45 min on a rotator at room temperature. Proteins were newly 
ethanol-precipitated in order to remove the remaining DTT. Protein pellet was 
dissolved in β00 μl of the previous buffer containing 0.η mM HPDP-biotin, a 
bifunctional reagent with an alkylating function at one end, and incubated 45 min on 
a rotator in the dark. Samples were ethanol-precipitated in order to remove the 
excess of HPDP-biotin and resuspended in ζ0 μl of 8ε urea and 1θ0 μl of η0mM of 
ammonium bicarbonate; an aliquot of η μl was used to measure protein 
concentration with Bradford assay. An equal amount of proteins from the two 
samples was tryptic digested (E/S ratio of 1:50) at 37°C overnight. After digestion, 
was added β00 μl of the denaturing buffer previously described. 
An appropriate quantity of 50% slurry streptavidin-agarose resin solution was 
prepared by two times washes in a binding buffer containing 4M urea, 2% CHAPS, 
25 mM Tris-HCl pH 8.0 and 50mM NaCl. Two same aliquots of agarose beads were 
incubated with each tryptic peptide mixtures overnight at 4°C on a rotator. Then, 
beads samples were washed once with the binding buffer, twice with wash buffer 1, 
(8M urea, 4% CHAPS, 25 mM Tris-HCl pH 8.0 and 1mM NaCl), and twice with 
wash buffer 2 (8M urea, 4% CHAPS, 25 mM Tris-HCl pH 8.0). In order to remove 
urea, the resin was finally washed four times with wash buffer 3 (5mM ammonium 
bicarbonate/20% acetonitrile). Peptides were at the same time eluted from 
streptavidine beads and cleaved from the cystein-HPDP-biotin bait by treatment 
with βη μl of elution buffer containing ηmε ammonium bicarbonate/β0% 
acetonitrile and 5% mercaptoethanol at 56°C for 10 min. Peptides were collected by 
centrifugation at 5000 rpm and stored at -80°C until mass spectrometric analysis. 
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3.6 Proteomic profilings 
3.6.a Bi-dimensional electrophoresis of proteins from the cytosolic and organelle 
compartments 
An equivalent amount (180 μg) from each of the cytosolic and membrane/organelle 
samples was desalted by precipitation with cold ethanol. The cytosolic pellet was 
resuspended with rehydration buffer containing 5 M urea, 2 M thiourea, 50 mM 
DTT, 2% w/v CHAPS, 0,2% v/v ampholytes pH range 3-10 (Bio-Lytes® 3/10, Bio-
Rad); the pellet obtained from the organelle fraction was resuspended in the same 
rehydration buffer described above, added with 2% w/v of amidosulfobetaine-14 
(ASB14) to improve the solubilization of membrane proteins. Samples were allowed 
to solubilize by mixing and incubating for 5 min at room temperature and loaded by 
passive rehydration on Immobiline linear pH 3-10 IPGTM strips, 11 cm long (Bio-
Rad). Isoelectric focusing (IEF) was performed with a Protean IEF Cell (Bio-Rad) at 
20°C using the following program: (i) 250 V for 15 min; (ii) 250 to 8000 V in 2.5 h; 
(iii) 8000 V for 4 h. 
After IEF, the proteins on the strip were immediately equilibrated for 2 times for 20 
min with 50 mM Tris-HCl, pH 8.8, in 6 M urea, 30% glycerol and 2% SDS. DTT 
(130 mM) was included in the first and iodoacetamide (135 mM) in the second 
equilibration step to reduce and alkylate free thiols. Precast SDS gel, 4-12% linear 
acrylamide gradient Bis-Tris midi gel (BioRad), was used for the second dimension 
separation by molecular weight. The IEF strip was carefully applied on top of the gel 
and fixed in position using warm agarose (0.5%) dissolved in MES running buffer 
[50 mM MES (2-[N-morpholino]ethanesulfonic acid), 50 mM Tris base,1 mM 
EDTA, 0.1% w/v SDS, pH 7.3]. A standard protein mixture (broad range; BioRad) 
was applied on a corner of the gel to determine the relative molecular masses of 
proteins. The gel was electro-run with MES running buffer applying a ramping 
voltage (from 100 V to 200 V). Proteins were detected by colloidal Coomassie 
staining. For each cellular fraction three replica were carried out. 
Digitized images of 2-DE gels were generated using GS-710 Densitometer 
(BioRad). Noise reduction, background subtraction, normalization, and quantitative 
profiling of proteins in 2-D gels were carried out using PDQuest software version 
8.0 (BioRad). For spot quantification, spot volumes were calculated with the 
building feature involving the application of a fixed multiple of Gaussian radius of 
the spot as a background intensity function. Subsequently, relative spot intensities, 
defined as percentage of spot volume to the sum of total spot volumes on the parent 
gel, were extracted from a spreadsheet generated by the software. All of the spots in 
each samples were matched by the automatic tool in PDQuest software. Where gel 
and spot quality strongly influenced the matching capabilities of the software used 
for protein quantitation, the replicate gels were critically reviewed for their 
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reproducibility. Subsequently, analysis sets were created to identify differentially 
expressed proteins between control and treated samples. Proteins identified in the 
majority of the replica and with a two-fold differential level of detection in the 
majority of the treated samples compared with control ones, were selected for mass 
spectrometry. 
3.6.b SDS-PAGE of immunoprecipitated complexes and plasma membrane 
enriched fractions 
Proteins co-immunoprecipitated with 14-3-γİ were partially resolved by mono-
dimensional SDS-PAGE gel in a Tris-glycine buffer system on pre-casted 4-12% 
polyacrylamide gels (BioRad). Mono-dimensional gels were stained by colloidal 
Coomassie. 
The same procedure was used to resolve and visualize proteins in the plasma 
membrane enriched fraction. 
3.6.c In-gel digestion  
Selected spots from the 2-DE and 1-DE were manually excised from the gels and 
submitted to in-gel digestion using a sequencing grade trypsin. Briefly, the excised 
gel pieces were destained with a solution of 50 mM ammonium bicarbonate 
containing 50% acetonitrile, dehydrated with 100% acetonitrile and speed-vac dried. 
The dried gel pieces were then rehydrated by adding about 10 μl of 25 mM 
ammonium bicarbonate containing 11 ng/μl of trypsin and incubated on ice. After 30 
min, more trypsin buffer was added, if necessary. Gel pieces were then incubate for 
16 h at 37 °C. 
3.6.d MALDI-TOF analysis of 2-DE spots 
A minimal amount (1 μl) of tryptic peptide mixtures derived from the digestion of 
2DE spots were analyzed by matrix-assisted laser desorption ionization (MALDI) 
time of flight (TOF) mass spectrometry by mixing the samples with a α-cyano-4-
hydroxycinnamic acid (HCCA) solution saturated in 50% acetonitrile/0.1% TFA in 
a 1:1 (v/v) ratio. The mixture was loaded onto the MALDI target using the dried 
droplet technique. MALDI-MS measurements were performed on a Voyager-DE® 
STR (Applied Biosystems) time of flight (TOF) mass spectrometer, equipped with a 
337 nm nitrogen laser and operating in reflector mode. In this analyzer, the ions 
travel down a flight tube and are turned around an ion mirror, or reflector, to correct 
for initial energy differences (Fig. 3.3). The m/z value is related to the time it takes 
an ion to reach the detector; the small ions have a higher velocity and are recorded 
on a detector before the larger ones. The ions are detected by a channel electron 
multiplier (Mann et al., 2001). 
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Fig. 3.3 The principle of MALDI-TOF MS. Ions are desorbed and ionized from the target plate and 
accelerate into the analyzer by an electric field of known strength. Here, the ions are separated 
according to their velocity that is strictly related to their m/z values. As MALDI source generates 
mono-charged ions, the m/z measured for each ion from the detector represents the mass value of a 
certain ion. 
Mass data were obtained by accumulating several spectra from laser shots with an 
accelerating voltage of 20,000 V. All MALDI mass spectra were externally 
calibrated using a standard peptide mixture containing des-Arg-Bradykinin (m/z 
904.4681), angiotensin I (m/z 1296.6853), 1-17 (m/z 2093.0867) and 18-39 (m/z 
2465.1989) adrenocorticotropic hormon fragments. The MS spectra were also 
internally calibrated with two tryptic autolytic peptides (m/z 842.5100 and 
2807.3145). The spectra were processed by MoverZ software (Proteometrics). A 
monoisotopic mass list from each MALDI-TOF spectrum was obtained after 
exclusion of contaminant mass values, corresponding to those expected from porcine 
trypsin and human keratins, automatically achieved by the PeakErazor program 
(http://www.protein.sdu.dk/gpmaw/Help/PeakErazor/peakerazor.html). 
Peptide mass fingerprints were used to search for protein candidates in SwissProt 
Mus musculus database (v. 2011_01, 524420 sequences, 185205850 residues), using 
MASCOT search engine (www.matrixscience.com) according to the following 
parameters: cleavage on Arg/Lys, up to two missed cleavage permission and a 
maximum error of 50 ppm. Carbamidomethylation of cysteine as fixed modification, 
oxidation of methionine and NH2-terminal protein acetylation as variable 
modification were also considered. 
3.6.e LC-MS/MS analyses 
Profiling of enriched fractions from plasma membrane, of 14-3-3İ interactomes and 
of the redoxome enriched by biotin-switch were performed on an LTQ-Orbitrap XL 
Discovery instrument (Thermo Fisher Scientific), a hybrid mass spectrometer in 
which two mass analyzers (a Linear Trapping Quadrupole and an Orbitrap cell) are 
built in tandem. Particularly, as suggested by the name, Orbitrap is an ion trapping 
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cell in which moving ions are trapped in an electrostatic field. However, unlike 
classic ion trap, the electrostatic attraction towards the central electrode is 
compensated by the centrifugal force arisen from the initial tangential velocity of 
ions. This electrostatic field experienced by ions inside the orbitrap forces them to 
move in complex spiral patterns strictly dependent on their mass value, like a 
satellite on orbit. The axial component of these oscillations is independent of initial 
energy, angles and positions, and can be detected as an image current on the two 
halves of an electrode encapsulating the orbitrap (Fig 3.4). A Fourier transform is 
employed to obtain oscillation frequencies for ions with different masses, resulting 
in an accurate reading of their m/z (Scigelova & Makarov, 2006).  
Such measurements achieve very high resolution (30,000) surpassing, by an order of 
magnitude, the resolution presently obtainable with orthogonal time-of-flight 
analyzers. Accordingly, by Orbitrap analyzer mass measurements at an extreme 
mass accuracy (less than 2 ppm) are possible. For these features, the orbitrap 
analyzer represents the election instrument for that proteomics applications in which 
low abundant proteins could be identified also from only one detectable peptide.  
Fig. 3.4 A cut-away model of the orbitrap mass analyzer. Ions are moving in spirals around a central 
electrode (a). An outer electrode (b) is split in half by an insulating ceramic ring (c). An image current 
induced by moving ions is detected via a differential amplifier  between the two halves of the outer 
orbitrap electrode. The m/z if different ions in the orbitrap can be determined from respective 
frequencies of oscillation after a Fourier transform (from Scigelova & Makarov, 2006). 
The LTQ-Orbitrap XL Discovery mass spectrometer was connected online with 
HPLC system (Ultimate 3000, Thermo Fisher Scientific) via a nanoelectrospray ion 
source (Thermo Fisher Scientific). 
The peptide mixture were desalted and concentrated using StageTip (Empore™ SPE 
Disks, C18, Sigma; Rappsilber et al., 2007); then, the mixture was autosampled onto 
7η μm x 10 cm, 8 μm inside-diameter, column packed in-house with η μm C18 
reversed-phase beads (Michrom Bioresources) and eluted with a gradient from 5% 
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to 80% of 0.1% formic acid in acetonitrile for 110 min. The MS data were acquired 
by the Orbitrap analyser in Full Scan mode over 300-2000 m/z range. Tandem mass 
spectra were acquired selecting parent ions into the Linear Trapping Quadrupole on 
the basis of Orbitrap measurements in a data-dependent scan mode (the most 5 
intense ions per orbitrap cycle), with a dynamic exclusion of ions already 
fragmentated. All these activities, particular critical to detecting and structural 
characterizing low abundant peptide ions, were automatically performance by the 
Xcalibur software (Thermo Fisher Scientific). 
3.6.f Mass spectra analysis 
Mass spectrometric data acquired by the LTQ-Orbitrap XL Discovery mass 
spectrometer were qualitative and quantitative analyzed off-line through the free 
available MaxQuant software (Cox et al., 2009). The MS and MSMS spectra were 
searched against Mus musculus database from UniprotKB. A maximum of two 
missed cleavages were allowed. The required False Discovery Rate (FDR) was set to 
0.01 at protein and peptide level. To increase statistical power the researches were 
achieved against a reverse decoy database. 
Carbamidomethylation of cysteine as fixed modification and oxidation of 
methionine as variable modification were also considered for the analysis of 14-3-γİ 
interactors and for the analysis of proteins enriched in plasma membrane fraction. 
For the analysis of redoxome captured by the biotin-switching bait, the following 
variable modifications were used: oxidation of methionine and cysteine, 
mercaptoethanol modification of cysteine, deamidation of asparagine and glutamine. 
 
3.7 Validation of proteomic identification by immunodetection 
An equal amount of proteins for each sample (18 μg per lane) was separated by 
SDS-PAGE in a Tris-Glycine buffer system on 0.75-mm-thick 12%polyacrylamide 
gels. Electrical transfer onto a nitrocellulose membrane was carried out with a wet 
electroblotting apparatus (BioRad) at 85 V for 90 min at 4°C using a buffer 
containing 25 mM Tris, 20mM glycine, and 20% methanol. The membrane was 
stained with 0.2% Ponceau Red in 0.3% TCA to check for successful of transfer. 
Then the membrane was treated with 5% ECL blocking agent (GE Healthcare 
Biosciences) in 0.1% Tween-20, 10 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl2, and 
1 mM MgCl2, pH 7.4 (T-TBS), for 1 h and then incubated with primary antibody 
overnight at 4°C. Subsequently, the membrane was washed three times in T-TBS, 
and bound antibodies were detected using appropriate horseradish peroxidase-
conjugated secondary antibodies, followed by an ECL Plus Western blotting 
Detection System (GE Healthcare Biosciences). ECL was detected using a Kodak 
Image Station 440cf (Eastman Kodak) and quantified using ImageJ analysis 
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software (http://rsbweb.nih.gov/ij/). Analysis was performed in triplicate from the 
two independent biological replicates. In each analyzed sample, target protein was 
relatively quantified by normalization to the corresponding GADPH level. Statistical 
analysis was performed applying T-student test; differences in protein expression 
with p-value of <0.05 were considered statistically significant. 
Antibody were purchased from the following sources: anti-14-3-3 (rabbit polyclonal 
antibody, sc-629, 1:500; Santa Cruz Biotechnology); anti-14-3-γİ (rabbit polyclonal 
antibody, sc-1020, 1:500; Santa Cruz Biotechnology); anti-glyceraldehyde-3-
phosphate dehydrogenase (anti-GAPDH, mouse monoclonal antibody, sc-32233, 
1:500; Santa Cruz Biotechnology) used as the primary antibody to confirm equal 
protein loading in each lane; anti rabbit IgG-HRP (goat antibody, sc-2350, 1:2000; 
Santa Cruz Biotechnology) and anti-mouse IgG-HRP (goat antibody, sc-2500, 
1:2000;Santa Cruz Biotechnology). 
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CHAPTER 4 
 
RESULTS 
 
The investigation on the role of microglia during sustained neuroinflammation 
induced by amyloidogenic peptides was achieved using as cell model BV2 cultures. 
This immortalized murine cell line (Blasi et al., 1990) shares functional properties 
with primary microglia (Henn et al., 2009; Stansley et al., 2012); accordingly, it is 
frequently used as a suitable cellular model in the field of neurodegeneration 
research. BVβ cells were challenged with the synthetic form of the Aȕ25-35 peptide, a 
shorter version of the full-length Aȕ1-42 peptide containing the neurotoxic domain, 
identified in vivo in the amyloid material accumulating in brains of patient with 
Alzheimer’s disease (Kaminsky et al., β010). This Aȕ25-35 has been proven to induce 
toxicological effects and oxidative burst on neuronal cells, overlapping those elicited 
by with Aȕ1-42 (Varadarajan et al., 2001). Unlike the native full-length peptide, Aȕ25-
35 could be solubilised in aqueous buffers and easily manipulated; this ensures 
physiological-like conditions in culture media and high experimental 
reproducibility. 
In our experimental setup, BVβ were treated with η0 µε Aȕ25-35, a concentration 
higher than that used in other studies, ranging between 0.1-10 με, in order to mimic 
the environmental conditions that could lead to a sustained pro-inflammatory 
microglia phenotype (Sondag et al., 2009; Schilling & Eder, 2011; Pan et al., 2011; 
Orellana et al., 2011; Dhawan et al., 2012). Moreover, in order to discriminate 
between the effects specifically ascribed to amyloid material and those due to a 
nonspecific perturbation, BV2 cells were treated in parallel experiments with the 
same amount of a synthetic peptide, made up from the reverse sequence of the Ab25–
35 peptide, named Ab35–25 or reverse peptide and known to miss the pro-inflammatory 
property (Ito et al., 2005). 
 
4.1 Characterization of amyloid-induced BV2 activation at cellular level 
Assays for viability of BV2 cells showed a marked proliferation upon the 
amyloidogenic treatment (Fig. 4.1 A) and an exocytotic response to specific drugs 
(cf. 3.3.a; Fig. 4.1 B; Liu & Schubert, 1997; Kreutzmann et al., 2010).  
Since one of the main microglial activities is the early secretion of soluble pro-
inflammatory factors, with the aim to validate our cellular model we first ascertained 
the specific ability of Aȕ25-35 peptide to induce in BV2 cells a specific inflammatory 
response. An increase in TNF-α transcription after γ h of stimulation with Aȕ25-35  
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Fig. 4.1 (A) Aȕ25-35 induces cell proliferation. After treatment for βζ and ζ8h with η0 µε Aȕ25–35 or 
Aȕ35-25, the number of BVβ cells was determined by cell counts, using trypan blue staining. (B) Aȕ25-35 
alters exocytotic function. BVβ cells were treated for βζ h with η0 µε Aȕ25-35 or Aȕ35-25 and then MTT 
reduction was performed. The absorbance of formazan solution was measured at 570 nm. T-test was 
used for statistical analysis; *indicates a significance of p<0.001. 
proved that this peptide was able to rapidly trigger an inflammatory response in 
microglial cells (Fig. 4.2 A). Furthermore, this pro-inflammatory commitment is 
long lasting, as IL-1ȕ protein remained over-expressed up to 48 h after stimulation 
(Fig. ζ.β B). The absence of cytokines release in the cells exposed to Aȕ35-25 peptide 
confirmed that only the amyloidogenic peptide was able to specifically trigger a pro-
inflammatory phenotype in microglia. 
Fig. 4.2. Induction of transcription of TNF-α (A) in BVβ cells treated for γ h with η0 µε Aȕ25–35 or Aȕ35-25. The TNF-α mRNA was detected by RT-PCR; the mRNA for GAPDH was used as reference. 
(B) The protein amount of IL-1ȕ was measured by EδISA. T-test was used for statistical analysis; 
*indicates a significance of p<0.001. 
 
4.2 Proteomics analysis of the cytosolic and organelle compartments 
An unbiased proteomics approach was used to highlight the molecular scenario of 
late events in neuroinflammation. With this aim, we chose a stimulation time of 24 h 
to allow a transcriptional remodeling of the BV2 proteome.  
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Proteomic analyses of resting and stimulated cells were performed on diverse 
cellular fractions in order to simplify protein mixtures and consequently improve the 
chances of protein identification (Di Francesco et al., 2012). We exploited two 
fractions of each cell lysate, respectively enriched with cytosolic or with microsomal 
fraction and proteins from the lumen of organelles, missing the nuclear components. 
Each sample was then analyzed by bi-dimensional gel electrophoresis (2-DE) 
comparing three analytical replicates from two independent biological replicates of 
each BVβ state (Aȕ25-35-, Aȕ35-25-treated and control cells).  
In control BV2 cells, approximately 230 and 130 protein spots were detected by 
Coomassie staining among all replicates of all cell fractions, respectively (Fig. 4.3). 
Qualitative and quantitative changes between 2-DE maps were then achieved by 
comparison of protein spot densities from all replica by a specialized software. Spots 
that showed a ≥β-fold change in intensity, or that were uniquely present in all 2-DE 
maps of treated cell fractions were excised (labeled spots in Fig. 4.3), and proteins 
were identified by MALDI-TOF peptide mass fingerprint (PMF; Table 4.1). 
Quantitative changes observed in the densitometric comparison between 2-DE gel 
spots of Aȕ25-35-activated cells versus Aȕ35–25-treated cells confirmed that the two 
diverse peptides (same composition but reverse sequences) induce different 
activation programs, with the respective molecular scenario actually distinctive, each 
being representative of two different response pathways. 
Six proteins were proved to be specifically down-regulated by an approximately 2-
fold factor in Aȕ25-35-treated cells in respect to the resting cell sample. Particularly, 
Hsp 90α/ȕ, galectin γ, and δ-lactate dehydrogenase A chain were down-regulated in 
the cytosolic fraction, whereas TOM 70, peroxiredoxins 3 and 4 were decreasing 
proteins in the membrane/organelle fraction. According to their annotated 
biochemical function, this inventory encompasses a molecular chaperon (Hsp 90), 
one metabolic enzyme (L-lactate dehydrogenase), two redox proteins 
(peroxiredoxins 3 and 4), one component of a mitochondrial membrane translocon 
(TOM70), and a lectin (galectin 3). Two of them had been previously associated 
with Alzheimer’s disease: Hsp 90 seems to enhance the clearance of Aȕ1-42 (Takata 
et al., 2003) and the TOM complex has been already demonstrated to be involved in 
mitochondrial Aȕ import (Hansson Petersen et al., 2008). 
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Fig. 4.3 Effects of Aȕ25–35 and Aȕ35–25 on 2-DE protein profiles of BV2. BV2 proteome was pre-
fractionated according to the Qproteome Cell Compartment Kit (Qiagen) into cytosolic proteins and 
microsomal/organelles proteins. Protein mixtures were separated using a linear pH 3–10 gradient strip 
for the isoelectrofocusing and a 12% polyacrylamide gel for the second dimension. Representative 2-
DE map of the resting BV2 cytosolic proteome (A) and microsomal/organelles proteome (B) are 
reported. Red circles refer to spots that showed ≥ β-fold changes in intensity or that were uniquely 
expressed in Aȕ25–35-treated BV2 cells. Their MALDI-TOF identifications are also reported, according 
to Table 4.1. 
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Notably, only two components of the entire BV2 proteome were up-regulated. The 
first was a more acidic species of the cytosolic actin, found in Aȕ25-35-stimulated 
BV2 2-DE profile, but not in those of control and of reverse peptide-treated cells 
(Fig. 4.4). 
Fig. 4.4 Representative βDE maps of the cytosolic fraction of control (A), Aȕ25–35 (B) and Aȕ35–25 (C) 
treated BV2 cells, zoomed in to focus on an acidic isoform of actin (arrow), found uniquely expressed 
in Aȕ25–35 samples. 
The second protein was the epsilon isoform of the protein 14-3-3, a family of 
conserved regulatory molecules expressed in all eukaryotic cells. This latter 
proteome signature was also validated by western blot analysis (p-value of 0.025 
versus control; Fig. 4.5 A). According to this validation, we planned to further 
decoding the 14-3-γİ role in microglia activation. 
Fig. 4.5 Effects of Aȕ25–35 and Aȕ35–25 on the expression of 14-3-3 proteins. Immunodetection of the 
14-3-3İ protein (A) and of the entire 14-3-3 family (B) in the cytosolic fraction of lysates from 
untreated BVβ cells (control) and cells treated for βζ h with η0 με Aȕ25–35 or Aȕ35–25, respectively. 
Quantification were performed normalizing the optical density to the 14-3-3İ band in each sample 
versus the corresponding GADPH optical density. Results are represented as a mean (±SD) of n=5 
replicates. Statistical analysis was performed by Student’ T-test. * p-value of 0.05 versus control; # p-
value of 0.002 versus control. 
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4.3 Defining the protein-protein interaction network of the epsilon 14-3-3- 
pathway in microglia toxic activation  
The 14-3-3 proteins belong to a complex family that participate into the cell 
proteome in a wide range of cellular processes through the binding with unrelated 
proteins. Several distinct mechanisms of the 14-3-3 protein function were described, 
including conformational modulation of the bound protein, masking of its sequence-
specific or structural features, and scaffolding that facilitates interaction between 
bound proteins (Obsil & Obsilova, 2011).  
With the aim to in depth characterize the specific involvement of 14-3-3 family 
components in the neuroinflammatory response to amyloid, level of the epsilon 
isoform was compared with the global expression of the entire family in the 
cytosolic fraction of lysates from BV2 cells, untreated and treated with Ab25–35 or 
Ab35–25 respectively. Whereas a decrease in the global expression of the 14-3-3 
proteins was immunodetected, the epsilon isoform fraction presents a dramatically 
and specific increase (Fig. 4.5 B).  
Aimed to corroborate the validity of these findings, more recently we concentrated 
efforts on a comparative characterization of the BV2 proteome specifically 
interacting with a tagged form the 14-3-γİ protein, conveniently expressed in cells 
by transient transfection. For disclosing differential expression patterns also at the 
level of minor components, we benefit of an advanced proteomic setup. In this 
platform, accuracy in measuring relative protein abundances of a quantitative mass 
spectrometry-dependent analysis (Stable Isotope Labeling with Aminoacids in Cell 
culture, SILAC; Ong & Mann, 2006) is coupled with the identification power of 
shot-gun proteomics (Wu & MacCoss, 2002) where proteins are identified on poorly 
resolved mixtures, with the evident advantage to minimize component loss. 
Specifically, the SILAC approach measures differential protein expression through 
the ratio between unlabeled (from untreated cells) and stable isotope labeled (from 
treated cells) ion signals of protein peptides. Upon the biological treatment, labeled 
(amyloid treated cell lysate) and unlabeled (resting cell lysate) samples are then 
mixed, upstream of the proteomic sample preparation. The proteomic 
characterization of these high complex peptide mixtures strictly requires nano-liquid 
chromatography (nano-LC) hyphenated with highest resolution and fast mass 
spectrometry, such as that incorporated an “orbitrap” analyzer (εakarov, β000; Hu 
et al., 2005).  
According with this setup, proteins co-immunoprecipitated with 14-3-γİ were first 
resolved on SDS-PAGE gradient gel to reduce mixture complexity, and  the entire 
gel lane was cut in 11 slices each treated according to shot-gun proteomics. We 
identified by LC-MS/MS analysis 196 proteins immunoprecipitated with tagged 14-
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3-γİ. Among these proteins, several previously reported 14-3-γİ binding partners 
were present, e.g. 14-3-γș, 1ζ-3-γȗ /į (δiang et al., 2009; Chaudhri et al., 2003), 14-
3-γȕ/α, 1ζ-3-γȘ, 1ζ-3-γȖ (Chaudhri et al., 2003), ribosomal proteins S3 and P0, 
elongation factor 1-Ȗ, elongation factor 1-α, tubulin ȕ-2, poly(rC)-binding protein 1, 
Hsp 90 (Liang et al., 2009; Zuo et al., 2010), tropomyosin 3, glyceraldehyde-3-
phosphate dehydrogenase, cofilin-1, calmodulin (Liang et al., 2009) and vimentin 
(Satoh et al., 2004). 
Relative quantification of the identified proteins were then obtained comparing the 
heavy and light mass signals for each peptide identified by the LC-MS/MS, using a 
specialized open source software (MaxQuant). Quantitative data, collectable only 
from signals of protein peptides containing arginine residues on the basis of the 
experimental design we used, were expressed as H/L ratio (i.e. the ratio between 
signals of peptides labeled with a stable isotope enriched arginine residue, 10 amu 
heavier than peptide signals from untreated cells). Untill today, we carried out a 
single biological replica. According to this preliminary experiment, we found six 
proteins that were present only in the 14-3-γİ interactome following Aȕ25-35 
treatment (Table 4.2). Among these proteins there were gene products already 
annotated in protein data bases as involved in negative regulation of protein 
transport (lysophospholipase-like protein 1), meiosis (meiotic nuclear division 
protein 1 homolog), protein ubiquitination (protein Herc1), arginine metabolism 
(arginase-2) and protein import into mitochondrial matrix (mitochondrial 
translocator assembly and maintenance protein 41 homolog). Moreover, we found 
eight interacting proteins involved in the 14-3-γİ network only in resting BVβ cells. 
These proteins are annotated in protein data bases as involved in signal transduction 
(desmoglein 1-ȕ, protein phosphatase 1J, vomeronasal 1 receptor Cβγ), exocytosis 
(exocyst complex component 3-like protein 4), cell cycle regulation (katanin p80 
WD40-containing subunit B1), protein metabolism (insulin-degrading enzyme), 
establishment of cell polarity (serologically defined colon cancer antigen 8 
homolog) and actin cytoskeleton organization (nebulin-related-anchoring protein). 
Finally, 15 proteins showed a ≥ β-fold change in their H/L ratio. Among the 5 
proteins showing an higher level of association with the 14-3-γİ node were 
proteome components known to be involved both in remodeling of cytoskeleton 
(vimentin and annexin A2) and of other cellular structure (rootletin and protein 
SERAC1), and in DNA repair and maintenance (zinc finger Ran-binding domain-
containing protein 3). Conversely, the ten proteins displaying a decreased level of 
association are known to be involved in the immune response of microglia 
(lysozyme C-1 and peroxiredoxin-2), signaling pathway (peroxiredoxin-2, junction 
plakoglobin, sialoadhesin and adam 22), protein metabolism (ribosomal protein 
S20), lipid metabolism (patatin-like phospholipase domain-containing protein 2), 
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regulation of actin polymerization (actin-related protein 2/3 complex subunit 5), cell 
cycle regulation (enhancer of rudimentary homolog), regulation of gene expression 
(cryptochrome-1). 
Table 4.2 - Summary of proteomics identifications of 14-3-γİ interacting proteins 
displaying a differential detection in activated microglia. 
Protein ID a Protein names Ratio H/L b # peptides e PEP f 
Q3UFF7 Lysophospholipase-like protein 1 Aȕ-activated c 1 0.0016002 
Q8K396 Meiotic nuclear division protein 1 homolog Aȕ-activated c 1 0.029635 
E9PZP8 Protein Herc1 Aȕ-activated c 1 0.037794 
Q9D4Z5 Protein Prame Aȕ-activated c 1 0.047453 
O08691 Arginase-2, mitochondrial Aȕ-activated c 1 0.047677 
Q3TUH1 Mitochondrial translocator assembly and 
maintenance protein 41 homolog Aȕ-activated 
c 2 0.048394 
P20152 Vimentin 2.47 7 7.182E-223 
Q6NZP1 Zinc finger Ran-binding domain-containing protein 3 3.15 1 0.0091068 
P07356 Annexin A2 4.20 1 5.947E-170 
Q8CJ40 Rootletin 4.69 1 0.0010916 
Q3U213 Protein SERAC1 17.63 3 0.027651 
Q149T7 Protein phosphatase 1J Resting d 1 0.0028657 
Q6DIA2 Exocyst complex component 3-like protein 4 Resting d 1 0.005014 
Q9JHR7 Insulin-degrading enzyme Resting d 1 0.0077617 
Q7TSF1 Desmoglein-1 Resting d 1 0.011064 
Q8R2D1 Protein Vmn1r22 Resting d 1 0.017472 
Q80XB4 Nebulin-related-anchoring protein Resting d 1 0.021332 
Q8BG40 Katanin p80 WD40-containing subunit B1 Resting d 1 0.031362 
Q80UF4 Serologically defined colon cancer antigen 8 homolog Resting 
d 1 0.045869 
P97784 Cryptochrome-1 0.04 1 0.0056852 
P17897 Lysozyme C-1 0.18 1 1.1705E-62 
Q9CPW4 Actin-related protein 2/3 complex subunit 5 0.21 3 2.7825E-09 
Q9R1V6 Adam 22 0.45 1 0.0068393 
Q8BJ56 Patatin-like phospholipase domain-
containing protein 2 0.45 4 2.2939E-27 
Q62230 Sialoadhesin 0.46 2 1.289E-08 
Q02257 Junction plakoglobin 0.46 5 4.1954E-14 
Q61171 Peroxiredoxin-2 0.46 4 2.775E-11 
P60867 40S ribosomal protein S20 0.50 2 4.0612E-11 
P84089 Enhancer of rudimentary homolog 0.50 3 4.2683E-21 
a) UniProtKB protein identifier. 
b) SILAC H/L ratio determined by Maxquant software on the basis of mass spectrum analysis; a ratio higher than 1 
means an enhanced association, while a ratio lower than 1 means a reduced association. 
c) Protein associated only in the activated BV2 sample. 
d) Protein associated only in the resting BV2 sample. 
e) Number of peptides identified by MaxQuant search engine. 
f) Posterior error probability that is the probability of a false hit, calculated by MaxQuant. 
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4.4 Quantitative proteomic analysis of plasma membrane proteins during 
neuroinflammation 
Plasma membrane plays a fundamental role in microglial cells; its protein 
composition is not only involved in the stimulus recognition, but it is also essential 
in turning on activated cell populations. In analogy with the experimental setup 
conducted for the characterization of the 14-3-γİ network, we approached a 
comparative analysis of the BV2 plasma membrane by means of SILAC. The 
membrane pellets from resting and activated BV2 were 1:1 pooled and a fraction 
enriched in plasma membrane was isolated, according to its differential partition into 
a serialized two-phase system (Schindler et al., 2007). 
Proteins from this fraction were then partially resolved by SDS-PAGE on a gradient 
gel (Fig. 4.6). Peptide mixtures obtained upon cutting the entire lane in 11 slides 
were analyzed in triplicate by nanoLC-MS/MS, and 998 proteins were there 
identified at least in two replica.  
 
Fig. 4.6 Plasma membrane proteins enriched by two-phase partition. 
The selected protein fractions from untreated and Aȕ25–35-treated BV2 
cells were mixed in 1:1 proportion as described in the text. Proteins 
were resolved on a SDS-PAGE 4-20% gradient gel. After colloidal 
Coomassie staining, the gel was cut in 11 slice according to the dotted 
lines reported; the number of each slice is reported on the right. 
Molecular weight marker are also reported on the left. 
 
 
 
 
 
 
 
 
Relative quantification of 139 proteins, encompassed in this list and annotated in the 
gene ontology (GO) database as located in plasma membrane, was then performed 
by SILAC signals, i.e. comparing the MS signals of each couple of detected peptide 
ions encompassing “light” and “heavy” arginine residues, and expressed as H/δ ratio 
(Tab. ζ.γ). We found only four plasma membrane proteins with a ≥ β fold change in 
membrane abundance between resting and activated BV2. In particular, Hsp 60 (a 
marker of the cellular response to cell adhesion, according to its role in protein 
folding), syntenin-1 (a component of the signal transduction machinery) and 
syntaxin-binding protein 3 (already annotated as involved in exocytosis) were 
proved to increase its abundance abundance in the plasma membrane of activated 
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cells. Only the presence of integrin ȕ-6 (known to be involved in cell adhesion) 
showed to be less present at the plasma membrane level upon neuroinflammation. 
Table - 4.3 Summary of proteomics identification of plasma membrane associated proteins 
displaying a differential detection in activated microglia 
Protein ID a Protein names Ratio H/L b (±SEM) # peptides c PEP d 
Q9Z0T9 Integrin beta-6 0.2 ± 0.09 1 4.69E-13 
P63038 60 kDa heat shock protein, 
mitochondrial 
2.3 ± 0.09 9 0.000024 
O08992 Syntenin-1 2.5 ± 0.01 6 1.23E-292 
Q60770 Syntaxin-binding protein 3 6.4 ± 0.74 4 2.34E-09 
a) UniProtKB protein identifier. 
b) SILAC H/L ratio determined by Maxquant software on the basis of mass spectrum analysis; a ratio higher than 1 
means an up-regulation higher than 2-fold, while a ratio lower than 1 means a downregulation. 
c) Number of peptides identified by MaxQuant search engine. 
d) Posterior error probability that is the probability of a false hit, calculated by MaxQuant. 
 
4.5 Oxidative stress induced by Aβ25–35 in BV2 cells  
The relatively small differences depicted in the proteome profiles of Aȕ25-35-treated 
cells seems to suggest that, alternatively to the change of transcriptional levels, 
faster regulatory mechanisms are critical in pushing microglia into the 
neuroinflammatory state. For this reason, we very recently came to turn our 
proteomic approach in investigating protein post-translational modifications that 
specifically marked the microglia commitment by beta amyloid. Since microglial 
cells are the major source of ROS in injured brain and the production of these 
oxidants is crucial for both pro-inflammatory activity and survival, first we looked 
for an unbalanced redox state and for its possible effects on the microglia proteome 
in the later events of neuroinflammation. 
As mark of the microglia redox state, we first measured the intracellular glutathione 
concentrations at early (β h) and late (βζ h) times from the Aȕ25-35 treatment. The 
amount of total glutathione (GSx) showed a decrease already at 2 h after stimulation 
(Fig. 4.7 A). This decline is ascribable principally to the drop of reduced glutathione 
(GSH), the predominant cellular species (Fig. 4.7 B). The oxidized glutathione 
(GSSG), that usually represents only 1-1.5% of cellular GSx, conversely displayed 
an increased level both after 2 h and 24 h of treatment (Fig. 4.7 C). These augmented 
levels of GSSG caused a lowering of GSH/GSSG in the amyloid-treated samples 
with respect to the control one (Fig. 4.7 D).  
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Fig. 4.7 Aȕ25–35 induced changes in cellular glutathione content and ratio. GSH (B) and GSSG (C) were 
separated by HPLC and amperometrically measured after 2 h and 24 h from the stimulation. Total 
glutathione (A) and GSH/GSSG ratio (D) were calculated from the previous measures. Histograms 
represent the mean (± SD) of n=3 replicates. T-student was used for statistical analysis. * p≤ 0.0η.  
These results proved that Aȕ25-35 peptide does induce a change in the redox balance 
of microglial cells; moreover, a doubling of carbonyl groups on proteins after 72 h 
of treatment with Aȕ25-35 strongly suggests that the microglia could indeed sustain a 
long term oxidative stress, but with a significant effect on the proteostasis 
mantainence (Fig. 4.8). 
 
Fig. 4.8 Aȕ25–35 induced long term oxidative effect on BV2 
proteins. Protein carbonyls were measured after 72 h form 
stimulation with Aȕ25–35 by colorimetric assay using 2,4-
dinitrophenylhydrazine (DNPH). Histograms represent the 
mean (± SD) of n=3 replicates. T-student was used for 
statistical analysis. * p≤ 0.05. 
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4.6 Redox shotgun proteomics for the identification of reversibly oxidized 
proteins 
Cysteine residues in proteins represent one of the major proteome sensitive target of 
the intracellular oxidative stress. In particular, the level of reversible oxidative 
modification are nowadays investigated as a crucial step for global regulation of 
cellular activities (Dalle-Donne et al., 2008; Ghezzi, 2013). 
Once we determined an altered redox potential inside the activated microglia 
population, we became interested in looking for possible BV2 proteome components 
whose biochemical function are modulated by amyloid activation through a 
reversible modification on cysteine residues. For this purpose, we investigated the 
proteome of Aȕ25–35-treated BV2 cells using the highly sensitive shotgun strategy, 
recommended for detecting also low-abundance components. Due to the instable 
nature of reversible redox modified cysteines, we employed an approach to 
specifically enrich proteins encompassing reversible modified cysteines as stable 
derivatives upstream of the proteomic analysis (“biotin switch”, cf. 3.5.d). With the 
aim to overcome the experimental variability arisen from both the high dynamic 
range expected in the intracellular level of each cysteine modification and from the 
higher number of proteome manipulations to be carried out, protein identifications 
and quantitative data were globally achieved without any labeling through the 
comparison between peak intensities of all proteolitic peptides identified from the 
untreated and Aȕ25-35-treated cells by MS/MS. A total of twelve analyses were 
performed on two technical replicates for each of the three biological replicates for 
treated and untreated samples . 
From a total of 1022 peptides containing redox modified cysteines identified at least 
in one of these twelve samples, only 308 peptides were taken into account since they 
were identified in all three independent biological replicates. The summary of all 
these peptides is reported in Appendix I. 
Among these peptides, 122 peptides were specifically enriched from amyloid treated 
cells, 90 from the resting BV2, and 96 were found in both the two samples. 
Particularly among this latter group, in sample isolated from amyloid treated cells 
with respect to resting ones 6 peptides showed a significant (by at least a 2-fold 
factor) increase in abundance, and 18 peptides were found significantly less 
abundant (Fig. 4.9 and Table I in Appendix I). 
Turning on to proteins identified through these peptides, since some of the captured 
cysteines belong to the same protein the total number of redox-ome components 
specifically identified was 80 in lysates from amyloid treated cells, 64 in the samples 
from the resting cells, and 81 in both samples. Notably, among this latter group 15 
proteins were differentially modified at the same cysteine residue between the 
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treated sample and the untreated one, and in 13 proteins the oxidized cysteine 
occupied a different position in the sequence in the sample isolated from amyloid-
treated cells with respect to the control ones (Table I in Appendix I). These latter 
findings seem to highlight a highly specific switching code for regulation of 
proteome activities in response to the redox burst.  
 
Fig. 4.9 Pie chart of peptides identified as redox reversible modified by biotin-switch enrichment and 
LC-MS/MS analysis. 
In order to globally highlight the biological processes susceptible to this oxidative 
control of cell activities, we submitted to the DAVID (Database for Annotation, 
Visualization an Integrated Discovery) tool the database entry names of the 172 
proteins for which redox-modified peptides were specifically isolated, distinguished 
them in two lists according to the cell condition in which the higher level of redox 
modification was observed. Twelve major biological processes emerged from this 
analysis (Fig. 4.10). In the Aȕ25–35-treated BV2, the most affected class was 
represented by proteins involved in proteostasis maintenance (e.g. ribosomal 
proteins, elongation factors, and chaperones and mRNA processing). Moreover 
stress response, cytoskeleton remodeling (named protein complex assembly) and 
purine metabolism were proven as further emerging processis according 
bioinformatics. In particular, in the purine metabolism Rac1 and Rac2 (ras-related 
C3 botulinum toxin substrate 1 and 2) proteins, known to be involved in the 
activation of NADPH oxidase complex, are included. 
Beside proteins annotated into the main microglia processes affect by amyloid, we 
also found two proteins whose function was reported as regulated by cellular redox 
potential, i.e. the glyceraldehyde 3-phosphate dehydrogenase, a well-known 
moonlighting protein, that could relocate in the nucleus and act as a regulator of 
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gene expression (Brune & Lapetina, 1996), and the chloride intracellular channel 1 
(CLIC1), a metamorphic protein existing in a cytosolic and an integral to plasma 
membrane form (Tulk et al., 2002).  
Fig. 4.10 Major processes regulated by differential oxidation. Biological processes enrichment analysis 
was performed inspecting PANTHER database through DAVID online tool. 
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CHAPTER 5 
 
DISCUSSION & CONCLUSIONS 
 
The comprehension of the molecular basis that lead microglia to assume sustained 
neuroinflammatory phenotypes during neurodegenerative processes could be 
inferred through the analysis of changes in protein expression levels and the analysis 
of dynamic post-translational modification (PTM) of proteins during a chronic 
stimulation with Aȕ peptides. 
 
With this aim, during the PhD fellowship I focused my research activity on 
characterizing with the unbiased tool of proteomics, the protein landscape ofa 
cellular model of the Alzheimer’s disease (Stansley et al., 2012).The immortalized 
BV2 cell line,an established substitute for primary microglia, has been used to 
capture information on the events triggering a long-term neuroinflammations. 
 
A picture of the neuroinflammatory process as global as possible was achieved 
collecting molecular details on different sub-proteomes (i.e. soluble and plasma 
membrane proteins, and cysteine redox reversible PTMs). For this purpose, classical 
proteomics approach and advanced quantitative strategies were applied. 
 
Comparison of proteomic maps on cytosolic and organelle proteins (cf. 3.6.a) 
showed only seven proteins involved in the signature of the amyloidogenic peptide-
activated microglia. Most of the identified proteins showed a decrease in their 
expression level, suggesting a slight decrease in the global levels of expression, and 
thus evocating alteration on mechanisms of proteostasis.  
Despite this event, we were able to identify two proteins whose expression increased 
in stimulated BV2, that therefore might be candidates as suitable biomarkers of the 
microglia commitment toward neuroinflammation.  
Of these proteins, the former is an acidic variant of the cytosolic actin ascribable to a 
PTM lowering its pI, i.e. phosphorylation or nitration. The first trait of microglial 
activation is the change in the cytoskeleton architecture, which ultimately leads to 
the loss of the membranous processes and to the acquisition of amoeboid features, 
including migration and phagocyte properties (Bernhart et al., 2010). Accordingly, 
the presence of this actin species in activated BV2 may suggest its role in processes 
related to cytoskeleton remodeling, as the morphological change during the 
transition from resting to the activated cells (Plantier et al., 1998; Abd-El-Basset et 
al., 2004). Furthermore, actin re-organization may be a pre-requisite for endocytosis 
and macropinocytosis, events involved in the extracellular removal of Aȕ in 
microglial cells (Mandrekar et al., 2009). Finally, when microglia act as a 
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phagocyte, different states of actin cytoskeleton can enhance assembly and activity 
of NADPH oxidase, a multicomponent enzyme complex that, upon activation, 
produces the highly reactive free radical superoxide (Rassmussen et al., 2010). 
The latter marker of microglia activation we found, was the epsilon isoform of 14-3-
3 proteins. This isoform is a member of the 14-3-3 protein family involved in 
multiple cell processes, as proliferation, differentiation, transformation, and 
apoptosis (Aitken, 2006; Morrison, 2009). The 14-3-3 proteins are expressed in all 
cell types and tissues, and are coded by seven different genes in mammals. They are 
constitutively associated to form homo/heterodimers and can bind various 
structurally and functionally unrelated proteins thanks to their highly conserved 
peculiar folding (Obsil & Obsilova; Fig. 5.1 A).The only common feature shared by 
14-3-3 interacting proteins is a non-stringent binding motif containing mainly 
phosphorylated serine residues(Fig. 5.1 B). Since their interactors are both kinases 
and their substrates, 14-3-3 proteins play a relevant role in the regulation of signal 
transduction, cell cycle and intracellular trafficking. 
 
Fig. 5.1 (A) Side view of the crystal structures of human 14-3-γİ protein bound to a phosphopeptide (in 
yellow; from Gardino et al., 2006). (B) The protein sequences of the main14-3-3 binding motifs (i.e. 
mode I or mode II), where X is any type of residue and the phosphorylated serine is highlighted. 
 
The importance of the 14-3-3 protein family in the neuronal compartment and their 
participation in neurodegenerative disease is today an established issue (Berg et al., 
2003). In cerebrospinal fluid (CSF), 14-3-3 proteins have long been associated with 
the establishment of neurodegenerative diseases including AD (Jayaratnam et al., 
A
B
- R – S – X – S – X – P -
- R – X – Y/F – K – S – X – P -
Mode I
Mode II
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2008), and to date their presence in cerebrospinal fluid is able to assist in the 
diagnosis of Creutzfeldt–Jakob disease (Zerr et al., 2000). In the glia compartment, 
isoforms gamma and zeta were correlated to the immune response and to the 
secretion of pro-inflammatory cytokines in the models of Parkinson’s disease 
(Reynolds et al., 2009), and an altered level of isoforms epsilon, gamma, and zeta 
were found in the hippocampus of AD patients (Di Domenico et al., 2009). 
Furthermore, in astrocytes, which together with microglia represent the reactive cells 
of nervous system, the 14-3-3 epsilon seems to play a role in the reorganization of 
intermediate filaments network, and its overexpression is a marker of activation 
following the demyelination process (Satoh et al., 2004). This isoform is also 
present at high level specifically in several brain regions of patients with AD (Berg 
et al., 2003; Layfield et al., 1996), although its role in AD pathogenesis is still 
unclear. Despite an increasing general concern on this protein family, very limited 
data are today available for the presence and the functional role of 14-3-3 in 
microglia cells. 
 
To identify 14-3-γİ-mediated signaling pathways involved in the specific microglia 
response to amyloid, we selectively isolated complexes associated to this protein. 
The proteomics approach we applied (cf. 4.3), allowed us to prove that amyloid does 
induce a significant re-organization in the 14-3-γİ network, turning on or off 
signaling pathways (Table 4.2). Since all the partners detected by co-
immunoprecipitation with 14-3-γİ were absent in the βDE-maps, the approach we 
used successfully succeeded in highlighting minor component of the activated 
microglia scenario. Thanks to the quantitative implementation we employed in co-
immunopecipitation of 14-3-γİ, we successfully gain another level of information on 
the proteomic landscape followed microglia activation. The difference in abundance 
of some partners detected in the 14-3-γİ interactomes could be ascribed to i) 
difference in their expression level; ii) increase their affinity due to possible 
conformational transition, triggered by post-translational modification or by an 
allosteric effector; iii) their release in the activated microglia from cellular 
compartments or complexes belonging to other signaling networks, that caused their 
sequestration in the resting cells. These results, even if preliminary, represent the 
first description of signaling complexes inside the activated microglia. Further 
studies will be necessary to validate the 14-3-γİ interacting partners, also at post-
translational level, in order to understand how they could influence the pro-
inflammatory activity of microglia. 
 
Both these reported studies describe the expression proteome at the cytosolic level. 
However the first cellular site where amyloid and microglia encounter is the plasma 
membrane. A comparative profiling of complexes that dynamically associate with 
plasma membrane is demanding to complete the overview of modulation that occur 
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at the proteomic level in amyloid-activated microglia. Profiling of the plasma 
membrane proteins is still a challenge, since usually mitochondrial and 
endoplasmatic membrane proteins are overwhelming. With the aim to selectively 
enrich the membrane protein fractions in plasma membrane proteins, we approached 
a protocol based on a two-phase partition of cell membranes able to discriminate 
different lipid compositions (Schindler et al., 2007), slightly modified to encompass 
in these profiles also proteins that associate with membrane complexes (cf. 3.5.c). 
Among various efficient protocols recently employed (Stella et al., 2012), we have 
selected the method used by Schindler and colleagues for the promising results 
obtained in plasma membrane proteins enrichment. 
 
Noteworthy, 139 proteins identified in the profile are already proved to be integral 
or associate plasma membrane proteins, according to Gene Onthology database 
annotation (http://www.geneontology.org/). 
Among these 139 proteins, only three of them become enriched on plasma 
membrane after Aȕ stimulation, and hence could mark the activated pro-
inflammatory microglia, namely syntaxin-binding protein 3, Hsp 60 and syntenin-1. 
Syntaxin-binding protein 3 is involved in the exocytosis mediated by SNARE 
complex and has been proved to be expressed not only in neurons but also in other 
glial cells, including microglia (Paco et al., 2009); furthermore, this protein, together 
with syntaxin 4, regulates cytokines secretion in macrophages activated by LPS 
(Pagan et al., 2003). Hsp 60, known for its chaperone activity, seems to be involved 
in the immune response when exposed on external side of plasma membrane, 
particularly in antigen presenting cells (Belles et al., 1999), as proved in T 
lymphocytes activation (Osterloh et al., 2004). Syntenin-1 is an adaptor protein 
mainly involved in the re-organization of cytoskeleton; indeed, it is involved in cell 
motility through the activation of signaling pathways governed by MAPK and NFkB 
(Boukerche et al. 2008), in T lymphocytes cell polarization and migratory response 
(Sala-Valdès et al. 2012) and receptor trafficking (Zimmermann et al., 2005). 
The relatively small differences depicted in the proteome profiles of Aȕ25-35-treated 
cells seem to suggest that, alternatively to the change of transcriptional levels, faster 
regulatory mechanisms are critical in pushing microglia into the neuroinflammatory 
state. For this reason, we, very recently, came to turn our proteomic approach in 
investigating PTM that specifically marked the microglia commitment by beta 
amyloid. Since microglia cells are the major source of ROS in injured brain and the 
production of these oxidants is crucial for both pro-inflammatory activity and 
survival, we looked for the intracellular redox state. 
 
The GSH/GSSG ratio, a good measure of redox state, was proven to decrease to a 
lower value in amyloid-stimulated microglia with respect to the resting cells, but it 
remained constant for an expanded time range (upon 48 h), suggesting that microglia 
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is able to sustain the oxidative injury elicited by the amyloid challenge stabilizing a 
chronic lower redox state. This peculiar feature of microglia, makes them a reliable 
model to investigate the redox protein modification as a switch for lighting their 
functional role in neuroinflammation. 
 
We started to analyze the microglia redox-ome, namely the entire set of proteome 
components whose cysteinyl residues are covalently modified and that could play a 
pivotal role in the dynamic regulation of protein function(Chiappetta et al., 2010). 
Recent evidences suggest a relevant regulatory role in cell signaling for a set of 
reversible redox modifications(e.g. S-nitrosylation, S-glutathionylation, disulfide 
bond and sulfenic acid formation). Among them, S-glutathionylation is looked at 
with particular expectation since its intracellular level depend on an enzymatic 
controlled activity. Glutathionylation and de-glutathionylationare catalyzed by a 
specific class of enzymes, named glutaredoxins (Lillig & Berndt, 2012). Although a 
clear consensus for the molecular recognition between glutaredoxin and its 
substrates is not yet be determined, specificity could be achieved by structural 
requirement as the accessibility of the cysteine (Malvezzi et al., 2012). Beyond 
glutathionylation, also for nitrosylation the involvement of specific enzymes has 
been tentatively suggested (Janssen-Heininger et al., 2008). 
 
The transient trait of reversible redox modifications and their chemical instability 
both contribute to make their targeted capture a difficult task in proteomics (Fratelli 
et al., 2002; Newman et al., 2007; de Luca et al., 2011). In a preliminary setup of 
experiments, we tried to specifically resolve the S-glutathionated proteome on 2DE 
maps by immunodetection, but with a very low degree of reproducibility. On the 
contrary the biotin-switch method we approached ensured us the required level of 
reproducibility and allowed us to map modified cysteines on the structure of 
identified proteins (Table I in Appendix I), although it should be make clear that this 
procedure is not specific for S-glutathionylation (McDonagh et al., 2009). 
Particularly, this intrinsic feature of the biotin-switch enrichment in respect to other 
methods highlighted that a redox modification may impact on the same protein in 
the resting and activated microglia, but involving different cysteines in its sequence. 
Once this redox-ome will be immuno-resolved for S-glutationylation, those 
cysteines differentially modified will represent a sort of molecular barcode for 
extrapolating consensus sequences and for looking for enzymatic activities acting in 
activated microglia. 
 
Redox modified cysteines we found, were in proteins involved in different 
biological processes, the proteostasis being the major affected process, as already 
inferred by results of expression proteome above discussed. It is important to 
underline that in amyloid activated microglia, where a chronic oxidative stress is 
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setup, a significant number of cysteine residues, proven to be redox modified in 
resting cells, was missed. If these events depend on a further modification leading to 
an irreversible oxidation state (e.g. sulphonylation), or on an enzymatic driven 
reduction, is still to be assessed. In the former case, the event will be stochastic and 
with a poor regulative significance; in the latter, a regulation of the signaling 
pathway leading to microglia activation could be hypothesized. 
 
Among the proteins specifically redox modified in the activated microglial cells, 
three proteins aroused our interest for their correlation with microglial neurotoxic 
activity. Two of these are small GTPases, belonging to the Rho GTPase family, that 
in their active form can bind different protein effectors related to secretory pathways 
(Humeau et al., 2002), phagocytosis (Yamauchi et al., 2004) and apoptosis (Embade 
et al., 2000), namely Ras-related C3 botulinum toxin substrate 1 (Rac1) and Ras-
related C3 botulinum toxin substrate 2 (Rac2). Rac1 and Rac2 represent, together 
with p40phox, p47phox and p67phox, the cytosolic regulatory subunit of the 
NADPH oxidase complex (Fig. 5.2; Babior, 1999). In the resting microglial status, 
inactive GDP-bound Rac1/2 are sequestered in the cytosol by Rho GDP-dissociation 
inhibitor (RhoGDI). After microglial activation, Rac1/2 is activated through GTP-
binding, dissociates from RhoGDI and can translocate on plasma membrane where 
contributes to NADPH oxidase activation (Wilkinson & Landreth, 2006). Hence, the 
redox reversible modification we determined for these two proteins allowed us to 
suggest that the modified isoform of these proteins could be involved in the 
extracellular ROS production and the neurotoxic activity of microglia during chronic 
amyloid injury. 
Fig. 5.2 Activation of the phagocytic NADPH oxidase complex. Stimulation of the phagocyte induces 
the parallel activation of oxidase components within the cytoplasm. This activation causes the 
conversion of Rac into an active GTP-bound form and the phosphorylation of p47phox and p67phox. 
Upon activation, these subunits translocate to the membrane where they interact with p22phox and 
gp91phox to initiate reactive oxygen production (from Wilkinson & Landreth, 2006). 
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Another relevant proteins identified in the redox-ome is the chloride intracellular 
channel 1 (CLIC1), a member of the CLICs family of highly conserved chloride 
channel proteins. Six different isoforms have been identified in vertebrates (CLIC1-
6), homologous to those identified in invertebrates (Littler et al., 2010) and in plants 
(Elter et al., 2007). Despite this evolutionary conservation, their precise function 
remains elusive. Nevertheless, these proteins are involved in many physiological 
processes such as cell division (Valenzuela et al., 2000; Berryman & Goldenring, 
2003), cell cycle and apoptosis (Shiio et al., 2006), cell differentiation (Suh et al., 
2007), and also in pathophysiological processes such as pulmonary hypotension 
(Laudi et al., 2007), neurodegenerative diseases (Novarino et al., 2004) and different 
type of cancer (Suh & Yuspa, β00η). These proteins are named “metamorphic” as 
they exist under two different species: a soluble and an integral membrane forms 
(Valenzuela et al., 1997; Tulk et al., 2002). A recent study on CLIC1 reported that 
the incubation with hydrogen peroxide leads to the formation of an intramolecular 
disulfide bridge between Cys24 and Cys59, responsible for a non-covalent 
dimerization of the protein. This dimeric unit is able to form an ion channel in an 
artificial lipid bilayer, structurally similar to the native membrane (Littler et al., 
2004). The N-terminal region encompassing Cys24 to Val46 has been proposed as 
the domain that upon oxidation drives the insertion of the protein into the lipid 
bilayer, through a conformational transition (Fig. 5.3; Littler et al., 2004; Goodchild 
et al., 2009). Once into the plasma membrane, CLIC1 can oligomerize forming an 
ion channel for the influx of chloride ions altering the membrane ionic conductance. 
Treatment of microglial cells with amyloid induces its localization on plasma 
membrane, and CLIC1 silencing alter both the release of TNF-α and NO production 
(Novarino et al., 2004). Moreover, blockade of CLIC1 stimulates amyloid 
phagocytosis in mononuclear phagocytes (Paradisi et al., 2008). Recently, it has 
been proposed that CLIC1 could modulate macrophagic activity through the 
modulation of phagosomal acidification (Jiang et al., 2012). 
In our analysis, we do not find as redox modified neither Cys24 norCys59, involved 
in the stabilization of CLIC1 dimer; this is probably due to the reduction of the 
disulfide bridge between them during the insertion in the lipid bilayer, as proposed 
by Goodchild and colleagues (2010). Conversely, Cys191 was demonstrated to be 
specifically redox modified upon amyloid stimulation. In the proposed structural 
model of the plasma membrane inserted CLIC1, this cysteine is located in the 
cytosolic C-terminal region of the protein (Fig. 5.3 B; Goodchild et al., 2010). 
Therefore, this specific cysteine could be involved in regulation and structural 
stabilization of the CLIC1 isoform anchored to the plasma membrane. 
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Fig. 5.3 Current proposed model of CLIC1 membrane insertion (A). Upon oxidation, the soluble 
CδIC1 monomer undergoes a reversible structural transition to an all α-helical, non-covalent dimer in 
solution. It has been proposed that in the presence of the membrane, the hydrophobic surface that forms 
the dimer-interface may dock to the bilayer as an initial step in the process of membrane insertion. The 
second stage in the process of membrane insertion involves insertion of the N-terminus across the lipid 
bilayer. Here, different CLIC1 subunits can converge to form an active ion channel (from Goodchild et 
al., 2009). (B) Model of the CLIC1membrane form (adapted from Goodchild et al., 2010). 
 
A 
B C191 
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In conclusion, our overall data provide a preliminary but comprehensive picture of 
microglia proteome involved in amyloid activation, and prepare the ground for 
further exploration of single pathways highlighted by this study. 
Particularly, the integrated view we provide, suggests that: 
a)  in later events of neuroinflammations, post-translational regulation rather than 
transcriptional one play a leading role in microglialneuroinflammatory activity; 
b)  cytoskeleton remodeling could play an important role in shaping not only cell 
morphology but also the microarchitecture of membrane complex 
c) an increased intracellular traffic (exocytosis) accompanies and sustains activated 
microglia; 
d)  redox dependent modifications seem to affect neurotoxic function of microglia, 
e.g.by the modulation of NADH oxidase through Rac1/2 activation turnover, 
and by the alteration of ionic conductance of the membrane though the 
stabilization of CLIC1 into the plasma membrane. 
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Table I - Differentially redox modified proteins identified by “biotin-switch” approach 
Protein ID a Protein name Reversible oxidized Cys detected b 
Reversible oxidation 
annotated c 
P14869 60S acidic ribosomal protein P0 Cys226 S-nitrosylation[18] 
P27659 60S ribosomal protein L3 Cys253 / 
Q9D8E6 60S ribosomal protein L4 Cys96, Cys125* Cys208 S-nitrosylation
[18]
 
P47962 60S ribosomal protein L5 Cys76 S-nitrosylation[8] 
P14148 60S ribosomal protein L7 Cys208 / 
P62918 60S ribosomal protein L8 Cys114, Cys115 / 
P35979 60S ribosomal protein L12 Cys141, Cys162 S-nitrosylation[9] 
P62717 60S ribosomal protein L18a Cys109 / 
P62830 60S ribosomal protein L23 Cys125 S-nitrosylation[15] 
P14115 60S ribosomal protein L27a Cys70 S-nitrosylation[9] 
P62889 60S ribosomal protein L30 Cys52, Cys92 / 
P62911 60S ribosomal protein L32 Cys91 / 
P47964 60S ribosomal protein L36 Cys48 / 
P83882 60S ribosomal protein L36a Cys72, Cys77 / 
P14206 40S ribosomal protein SA Cys163 S-nitrosylation
 [1]
 
S-glutathionylation[2] 
P25444 40S ribosomal protein S2 Cys229 S-nitrosylation[9] 
P62908 40S ribosomal protein S3 Cys97 S-nitrosylation[8] 
P97351 40S ribosomal protein S3a Cys139 S-nitrosylation[9] 
P62702 40S ribosomal protein S4, X isoform Cys41* S-nitrosylation
[9]
 
P62754 40S ribosomal protein S6 Cys12 Cys100* S-nitrosylation
[9]
 
P62242 40S ribosomal protein S8 Cys72, Cys100, Cys174 S-nitrosylation
[9]
 
P62281 40S ribosomal protein S11 Cys116 / 
Q6ZWZ6 40S ribosomal protein S12 Cys92 S-glutathionylation[3] 
P63276 40S ribosomal protein S17 Cys35 / 
Q9CQR2 40S ribosomal protein S21 Cys56 S-nitrosylation[18] 
P62267 40S ribosomal protein S23 Cys90 / 
Q6ZWU9 40S ribosomal protein S27 Cys59 S-nitrosylation[18] 
Q5XJF6 Ribosomal protein Cys66 / 
P10605 Cathepsin B Cys93 Disulfide bond # 
P06797 Cathepsin L1 Cys269 Disulfide bond # 
P18242 Cathepsin D Cys284 Disulfide bond # 
O70370 Cathepsin S Cys178 Disulfide bond # 
Q9WUU7 Cathepsin Z Cys156, Cys299 Disulfide bond # 
P35700 Peroxiredoxin-1 
Cys52* (active site), 
Cys71 
Cys83 
S-nitrosylation[6], 
S-glutathionylation[2] 
Sulfenic acid # 
O08709 Peroxiredoxin-6 Cys47 (active site) 
S-nitrosylation[4], 
S-glutathionylation [3] 
Sulfenic acid # 
Q9WV32 Actin-related protein 2/3 
complex subunit 1B;1A Cys162 / 
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Q99JY9 Actin-related protein 3 Cys235 / 
Q9QZB7 Actin-related protein 10 Cys291 / 
P13020 Gelsolin (actin depolimerizing factor) Cys329 S-nitrosylation
[6]
 
Q61233 Plastin-2 
Cys42, Cys164, 
Cys336, 
Cys460, Cys618 
S-nitrosylation[19] 
P18760 Cofilin-1 Cys39* Cys139* 
S-nitrosylation[4] 
S-glutathionylation[3] 
P20152 Vimentin Cys328 S-nitrosylation
[8]
 
S-glutathionylation[3] 
P68369 Tubulin alpha-1A Cys347 S-nitrosylation[1] 
P68372 Tubulin beta-4B chain,4A chain Cys12, Cys303 S-nitrosylation
[1] 
S-glutathionylation[2] 
Q60605 Myosin light polypeptide 6 Cys32 S-nitrosylation
[19]
 
S-glutathionylation[3] 
P11983 T-complex protein 1 subunit 
alpha Cys76 
S-nitrosylation 
S-glutathionylation 
P80318 T-complex protein 1 subunit gamma 
Cys173, Cys213, 
Cys455 
S-nitrosylation[8] 
S-glutathionylation[3] 
P80316 T-complex protein 1 subunit 
epsilon Cys302, Cys407 S-glutathionylation
[3]
 
P42932 T-complex protein 1 subunit theta Cys136 
S-nitrosylation[10] 
S-glutathionylation[3] 
P80313 T-complex protein 1 subunit eta Cys29*, Cys511 S-glutathionylation[3] 
P80317 T-complex protein 1 subunit 
zeta Cys406* 
S-nitrosylation[8] 
S-glutathionylation[3] 
P26041 Moesin Cys117 / 
O89053 Coronin-1A Cys285 / 
Q3TLP8 Ras-related C3 botulinum toxin 
substrate 1 Cys105 / 
Q05144 Ras-related C3 botulinum toxin 
substrate 2 
Cys105, Cys157, 
Cys178 / 
B2RXS4 Plexin-B2 Cys557 Disulfide bond # 
Q80TM9 Nischarin Cys884 / 
P14211 Calreticulin Cys105 S-nitrosylation
[7] 
Disulfide bond # 
P27773 Protein disulfide-isomerase A3 Cys244 S-nitrosylation
[8] 
S-glutathionylation[2] 
P63017 Heat shock cognate 71 kDa protein Cys603 
S-nitrosylation[6] 
S-glutathionylation[2] 
P07901 Heat shock protein HSP 90-
alpha Cys530 S-nitrosylation
 #
 
P11499 Heat shock protein HSP 90-beta Cys521 S-nitrosylation
[18] 
S-glutathionylation[2] 
P99029 Peroxiredoxin-5, mitochondrial Cys200* 
S-nitrosylation[8] 
S-glutathionylation[21] 
Disulfide bond # 
Q9CQN1 Heat shock protein 75 kDa, 
mitochondrial Cys135 S-nitrosylation
[6]
 
P08249 Malate dehydrogenase, 
mitochondrial 
Cys88, Cys93, 
Cys212, 
S-nitrosylation [13] 
S-glutathionylation[5] 
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Cys275, Cys285 
P05202 Aspartate aminotransferase, 
mitochondrial Cys295 / 
P47738 Aldehyde dehydrogenase, 
mitochondrial Cys388 
S-nitrosylation[13] 
S-glutathionylation[12] 
P56391 Cytochrome c oxidase subunit 6B1 Cys65 
S-glutathionylation[3] 
Disulfide bond # 
Q9DCX2 ATP synthase subunit d, 
mitochondrial Cys101 S-nitrosylation
[4] 
O08749 Dihydrolipoyl dehydrogenase, 
mitochondrial Cys477, Cys484 S-nitrosylation
[1]
 
Q8BFR5 Elongation factor Tu Cys122 S-nitrosylation[8] 
O88569 Heterogeneous nuclear 
ribonucleoproteins A2/B1 Cys50 S-nitrosylation
[1] 
P14152 Malate dehydrogenase, 
cytoplasmic Cys137 S-nitrosylation
[6] 
P05064 Fructose-bisphosphate aldolase A Cys290 
S-nitrosylation[1] 
S-glutathionylation[2] 
P06745 Glucose-6-phosphate isomerase Cys404 S-nitrosylation[1] 
P16858 Glyceraldehyde-3-phosphate dehydrogenase 
Cys150, Cys154 
Cys245* S-nitrosylation
[15] 
P17182 Alpha-enolase Cys337, Cys357*, Cys389* 
S-nitrosylation[19] 
S-glutathionylation[2] 
P17751 Triosephosphate isomerase Cys268 S-nitrosylation
[6] 
S-glutathionylation[3] 
P21956 Lactadherin Cys463 Disulfide bond # 
P30681 High mobility group protein B2 Cys106 / 
P50580 Proliferation-associated protein 2G4 Cys149 / 
P60335 Poly(rC)-binding protein Cys54 S-nitrosylation[15] 
P60843 Eukaryotic initiation factor 4A-I Cys66 S-nitrosylation[10] 
P63158 High mobility group protein B1 Cys106 S-glutathionylation[16] 
P63242 Eukaryotic translation initiation factor 5A-1,5A-2 Cys73 
S-nitrosylation[4] 
S-glutathionylation[2] 
P97429 Annexin A4 Cys108, Cys198 S-nitrosylation
[8] 
Q01768 Nucleoside diphosphate kinase B Cys260 
S-nitrosylation [6] 
S-glutathionylation[17] 
Q01853 Transitional endoplasmic 
reticulum ATPase Cys105 S-nitrosylation
[18] 
Q05816 Fatty acid-binding protein, 
epidermal Cys67, Cys87 
S-nitrosylation[7] 
S-glutathionylation[3] 
Q3U9N4 Granulins Cys98, Cys99, Cys183 / 
Q60930 Voltage-dependent anion-
selective channel protein 2 Cys77 / 
Q61598 Rab GDP dissociation inhibitor beta Cys302 S-nitrosylation
[18] 
Q6PDM2 Serine/arginine-rich splicing factor 1 Cys148 S-glutathionylation
[3] 
Q7TPV4 Myb-binding protein 1A Cys676 / 
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Q8BG05 Heterogeneous nuclear 
ribonucleoprotein A3 Cys64 S-nitrosylation
[8] 
Q8BP47 Asparagine--tRNA ligase, 
cytoplasmic Cys522 / 
Q8BTS0 Probable ATP-dependent RNA helicase Cys170 / 
Q8C2Q7 Heterogeneous nuclear 
ribonucleoprotein H Cys22, Cys267 S-nitrosylation
[8] 
Q8K114 Integrator complex subunit 9 Cys492 / 
Q8VEK6 Inhibitor of growth protein 3 Cys384, Cys393 / 
Q99K48 Non-POU domain-containing 
octamer-binding protein Cys147 / 
Q9D0I9 Arginine--tRNA ligase, 
cytoplasmic Cys86 / 
Q9DCD0 6-phosphogluconate dehydrogenase, decarboxylating Cys402 / 
Q9JIK5 Nucleolar RNA helicase 2 Cys754 / 
Q9QUI0 Transforming protein RhoA Cys16, Cys159 / 
P61079 Ubiquitin-conjugating enzyme E2 D3/E2 D2 Cys85, Cys107 
S-nitrosylation[18] 
S-glutathionylation[3] 
P26516 26S proteasome non-ATPase 
regulatory subunit 7 Cys116 S-nitrosylation
[18] 
Q9R1P4 Proteasome subunit alpha type-1 Cys85 / 
Q9R1P0 Proteasome subunit alpha type-4 Cys74 / 
Q9Z0J0 Epididymal secretory protein E1 
Cys93, Cys99, 
Cys140 Disulfide bond 
#
 
Q9Z1Q5 Chloride intracellular channel protein 1 Cys191 
S-nitrosylation[4] 
Disulfide bond # 
Q9Z2X1 Heterogeneous nuclear 
ribonucleoprotein F Cys290 / 
P17918 Proliferating cell nuclear 
antigen Cys135, Cys162 S-nitrosylation
[1] 
P51881 ADP/ATP translocase 2 Cys160, Cys257 S-nitrosylation[15] 
P61979 Heterogeneous nuclear 
ribonucleoprotein K 
Cys132, Cys145 
Cys185 S-nitrosylation
[8] 
P68040 Guanine nucleotide-binding protein subunit beta-2-like 1 
Cys138, Cys153, 
Cys182 
Cys240*, Cys249 
Cys286 
S-nitrosylation[1] 
Q60932 Voltage-dependent anion-
selective channel protein 1 Cys140, Cys245 S-nitrosylation
[13] 
Q61753 D-3-phosphoglycerate dehydrogenase 
Cys48, Cys281 
Cys369* S-nitrosylation
[6] 
O09131 Glutathione S-transferase 
omega-1 Cys237 
S-nitrosylation[4] 
S-glutathionylation[20] 
O55143 Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2 Cys1007 / 
P10126 Elongation factor 1-alpha 1 Cys411 S-nitrosylation
[8] 
S-glutathionylation[3] 
O70251 Elongation factor 1-beta Cys161 S-nitrosylation[1] 
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P57776 Elongation factor 1-delta Cys217 / 
 
P58252 Elongation factor 2 
Cys41, Cys466* 
Cys591, Cys693 
Cys751* 
S-nitrosylation[1] 
S-glutathionylation[14] 
O88587 Catechol O-methyltransferase Cys200 S-nitrosylation
[9] 
S-glutathionylation[20] 
P08030 Adenine phosphoribosyltransferase Cys140 S-nitrosylation
 [4] 
P08752 Guanine nucleotide-binding protein G(i) subunit alpha-2 Cys112 S-nitrosylation
[11] 
P08905 Lysozyme C-2 Cys95 Disulfide bond # 
P11835 Integrin beta-2 Cys247 S-nitrosylation
[8] 
Disulfide bond # 
P19096 Fatty acid synthase Cys274, Cys893 S-nitrosylation[9] 
P34884 Macrophage migration inhibitory factor Cys57 / 
P50247 Adenosylhomocysteinase Cys266 S-nitrosylation[9] 
P51660 Peroxisomal multifunctional 
enzyme type 2 Cys175 S-glutathionylation
[21] 
P51906 Excitatory amino acid transporter 3 Cys158 / 
P52480 Pyruvate kinase isozymes M1/M4 Cys152 
S-nitrosylation[6] 
S-glutathionylation[2] 
P61982 14-3-3 protein gamma Cys97 S-glutathionylation 
P68254 14-3-3 protein theta Cys94 / 
P62814 V-type proton ATPase subunit B, brain isoform Cys162, Cys258 / 
P84228 Histone H3.2 Cys111 / 
P84244 Histone H3.3 Cys111 / 
Q07076 Annexin A7 Cys260 S-nitrosylation
[8] 
S-glutathionylation[20] 
Q3TCU5 Tapasin Cys318 Disulfide bond # 
Q3TW96 
UDP-N-acetylhexosamine 
pyrophosphorylase-like protein 
1 
Cys271 / 
Q61035 Histidine--tRNA ligase, 
cytoplasmic Cys455 / 
Q61543 Golgi apparatus protein 1 Cys1067 / 
Q6P4T2 Small nuclear ribonucleoprotein 200 (U5) Cys133 / 
Q6P9L4 Ubiquitin carboxyl-terminal hydrolase 49 Cys259 (active site) / 
Q8BGQ7 Alanine--tRNA ligase, 
cytoplasmic Cys723, Cys947 / 
Q8BKC5 Importin-5 Cys1078 / 
Q8C605 6-phosphofructokinase Cys122, Cys342 S-nitrosylation[6] 
Q8CGC7 Bifunctional glutamate/proline--tRNA ligase 
Cys381, Cys856, 
Cys1309 / 
Q8K124 Pleckstrin homology domain-
containing family O member 2 Cys444 / 
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a) UniProtKB protein identifier. 
b) Specific redox modified cysteines, and their position in the protein sequences, identified in our 
experiments; in red are reported cysteines modified only after Aȕ25-35 stimulation, while in blue those 
modified only in the resting microglia. 
c) Revesrible redox modification previously reported in literature or in database for the listed proteins. 
* peptides containing cysteine with a statistical significant (p≤0.0η) and by at least a β-fold factor 
change in abundance after stimulation. 
# annotation as in UniprotKB database. 
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